<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">107096</article-id><article-id pub-id-type="doi">10.7554/eLife.107096</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.107096.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Epidermal resident memory T cell fitness requires antigen encounter in the skin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weiss</surname><given-names>Eric S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2352-0036</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hirai</surname><given-names>Toshiro</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Haiyue</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Shannon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Magill</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Gillis</surname><given-names>Jacob</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Youran R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Ramcke</surname><given-names>Torben</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kurihara</surname><given-names>Kazuo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>The ImmGen Consortium OpenSource T cell Project</collab><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Masopust</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Anandasabapathy</surname><given-names>Niroshana</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Harinder</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zemmour</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Mackay</surname><given-names>Laura K</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kaplan</surname><given-names>Daniel H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0598-0047</contrib-id><email>dankaplan@pitt.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>Department of Dermatology, University of Pittsburgh</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>Department of Immunology, University of Pittsburgh</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Institute for Microbial Diseases, Osaka University</institution></institution-wrap><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Institute for Open and Transdisciplinary Research Initiatives, Osaka University</institution></institution-wrap><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Department of Immunology, Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Center for Immunology, Department of Microbiology and Immunology, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02r109517</institution-id><institution>Department of Dermatology, Meyer Cancer Center, Program in Immunology and Microbial Pathogenesis, Weill Cornell Medicine</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>Center for Systems Immunology, University of Pittsburgh</institution></institution-wrap><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/016899r71</institution-id><institution>Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><addr-line><named-content content-type="city">Manhasset</named-content></addr-line><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>12</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP107096</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-04-11"><day>11</day><month>04</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2025-04-05"><day>05</day><month>04</month><year>2025</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.03.31.646438"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-07-02"><day>02</day><month>07</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107096.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-09-29"><day>29</day><month>09</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.107096.2"/></event></pub-history><permissions><copyright-statement>© 2025, Weiss et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Weiss et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-107096-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-107096-figures-v1.pdf"/><abstract><p>CD8<sup>+</sup> tissue-resident memory T cells (T<sub>RM</sub>) develop from effectors that seed peripheral tissues where they persist providing defense against subsequent challenges. T<sub>RM</sub> persistence requires autocrine TGFβ transactivated by integrins expressed on keratinocytes. T<sub>RM</sub> precursors that encounter antigen in the epidermis during development outcompete bystander T<sub>RM</sub> for TGFβ resulting in enhanced persistence. ScRNA-seq analysis of epidermal T<sub>RM</sub> revealed that local antigen experience in the skin resulted in an enhanced differentiation signature in comparison with bystanders. Upon recall, T<sub>RM</sub> displayed greater proliferation dictated by affinity of antigen experienced during epidermal development. Finally, local antigen experienced T<sub>RM</sub> differentially expressed TGFβRIII, which increases avidity of the TGFβRI/II receptor complex for TGFβ. Selective ablation of <italic>Tgfbr3</italic> reduced local antigen experienced T<sub>RM</sub> capacity to persist, rendering them phenotypically like bystander T<sub>RM</sub>. Thus, antigen-driven TCR signaling in the epidermis during T<sub>RM</sub> differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal T<sub>RM</sub> fitness.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>We are constantly exposed to a wide array of pathogens in our environment. This would be detrimental to our survival if it were not for the immune system’s ability to adapt. Each time the body encounters pathogens, it develops an immunological memory that allows it to mount a quick defense response. Recent research has shown that immunological memory is not confined to immune organs like lymph nodes and spleen. Instead, a large proportion is maintained in peripheral tissues at sites of prior infection.</p><p>These local cells, known as tissue-resident memory T cells (T<sub>RM</sub>), provide the first line of defense against repeated infections. T<sub>RM</sub> develop from circulating precursors of memory T cells after pathogen exposure and then permanently reside in these tissues. The ability to mount pathogen-specific responses is a hallmark of immunological memory. Therefore, knowing how prior antigen exposure shapes T<sub>RM</sub> development is critical for understanding peripheral immunity. However, the signals that drive T cells to become T<sub>RM</sub> remain incompletely understood.</p><p>Using an acute viral infection model in mice, Weiss et al<italic>.</italic> investigated how local infection affects the differentiation and function of T<sub>RM</sub> in the skin. T<sub>RM</sub> cells were generated through skin infection with a poxvirus strain, and immune responses were measured using immunofluorescence, flow cytometry, and approaches that distinguish circulating from resident T cells.</p><p>The results showed that T cells must encounter pathogen-derived antigens directly in the skin, in addition to in the lymph nodes, for the effective development of T<sub>RM</sub>, which are capable of mounting stronger recall responses. Their long-term survival in the skin depended on signaling through the transforming growth factor-β (TGFβ) pathway, which is activated by skin cells and enhanced in T cells that encountered pathogens within the epidermis.</p><p>T<sub>RM</sub> play important roles in cancer surveillance, pathogen clearance and vaccine response, but they can also contribute to disease when dysregulated, as seen in conditions such as psoriasis, vitiligo and graft-versus-host disease. Understanding the factors that promote TRM fitness may enable strategies for making these cells more effective in fighting infections. Further, TGFß represents a possible therapeutic target to selectively modulate T<sub>RM</sub> activity when these cells become harmful.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>resident memory T cells</kwd><kwd>skin</kwd><kwd>cd8</kwd><kwd>epidermis</kwd><kwd>tgfb</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/006zn3t30</institution-id><institution>National Institute of Arthritis and Musculoskeletal and Skin Diseases</institution></institution-wrap></funding-source><award-id>AR083713</award-id><principal-award-recipient><name><surname>Kaplan</surname><given-names>Daniel H</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>2T32AI060525</award-id><principal-award-recipient><name><surname>Weiss</surname><given-names>Eric S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5T32AI089443</award-id><principal-award-recipient><name><surname>Weiss</surname><given-names>Eric S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5R01 AR083208</award-id><principal-award-recipient><name><surname>Anandasabapathy</surname><given-names>Niroshana</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>5R01AR060744</award-id><principal-award-recipient><name><surname>Kaplan</surname><given-names>Daniel H</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Antigen-driven TCR signaling in the epidermis during CD8<sup>+</sup> T<sub>RM</sub> differentiation results in a lower TGFβ requirement for persistence and increased proliferative capacity that together enhance epidermal T<sub>RM</sub> fitness.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Tissue-resident CD8 memory T cells (T<sub>RM</sub>) are a highly abundant, non-circulating, long-lived subset of memory T cells that play an important role in protecting against re-infections (<xref ref-type="bibr" rid="bib26">Jiang et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Peng et al., 2021</xref>). T<sub>RM</sub> also provide immunosurveillance against neoplasia and are thought to be pathogenic in some autoimmune diseases (<xref ref-type="bibr" rid="bib42">Oguejiofor et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Virassamy et al., 2023</xref>; <xref ref-type="bibr" rid="bib58">Strobl et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Strong Rodrigues et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">van den Boorn et al., 2009</xref>; <xref ref-type="bibr" rid="bib69">Zhang et al., 2023</xref>; <xref ref-type="bibr" rid="bib54">Schunkert et al., 2021</xref>). In the skin, following infection with vaccinia virus (VV) or herpes simplex virus, T<sub>RM</sub> develop from CD8<sup>+</sup> T cell effectors (T<sub>EFF</sub>) that expand following priming in the lymph node and are recruited into the skin by inflammatory signals where they preferentially reside in the epidermis (<xref ref-type="bibr" rid="bib26">Jiang et al., 2012</xref>; <xref ref-type="bibr" rid="bib2">Allan et al., 2003</xref>; <xref ref-type="bibr" rid="bib5">Bedoui et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">Liu et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Reynoso et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Gebhardt et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Hirai et al., 2020</xref>). Unlike T<sub>RM</sub> in some tissues, re-encounter with cognate antigen in the skin is not required for T<sub>RM</sub> differentiation (<xref ref-type="bibr" rid="bib37">McMaster et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Lee et al., 2011</xref>; <xref ref-type="bibr" rid="bib32">Mackay et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Masopust et al., 2004</xref>). Epidermal T<sub>RM</sub> that encounter cognate antigen in the skin or bystander T<sub>RM</sub> that do not encounter antigen both develop with comparable efficiency and both express similar levels of the canonical T<sub>RM</sub> markers CD103 and CD69 (<xref ref-type="bibr" rid="bib47">Park et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>).</p><p>The cytokine transforming growth factor β (TGFβ) is required for cutaneous T<sub>RM</sub> development at multiple stages. TGFβ signaling in the lymph node during steady state epigenetically preconditions naïve CD8 T cells allowing for later T<sub>RM</sub> differentiation (<xref ref-type="bibr" rid="bib35">Mani et al., 2019</xref>). T<sub>EFF</sub> recruited into skin require TGFβ signaling for entry into the epidermis and differentiation into T<sub>RM</sub> (<xref ref-type="bibr" rid="bib33">Mackay et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Mackay et al., 2015</xref>). Once epidermal T<sub>RM</sub> have differentiated, these cells continue to require TGFβ signaling to retain epidermal residence. TGFβ is produced bound to the latency-associated peptide that prevents bioactivity until the complex is activated, which in the epidermis is mediated exclusively by activation via the integrins α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>8</sub> expressed by keratinocytes (<xref ref-type="bibr" rid="bib3">Aluwihare et al., 2009</xref>; <xref ref-type="bibr" rid="bib66">Yang et al., 2007</xref>; <xref ref-type="bibr" rid="bib65">Worthington et al., 2011</xref>). Epidermal persistence of T<sub>RM</sub> depends on autocrine TGFβ, which is transactivated by the integrins ⍺vβ6 and ⍺vβ8 (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Hirai et al., 2019</xref>). Inducible ablation in T<sub>RM</sub> of a required component of the TGFβ receptor (TGFβRII) or TGFβ1, as well as ablation of ⍺vβ6 and ⍺vβ8 in keratinocytes, all result in loss of epidermal T<sub>RM</sub> (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>; <xref ref-type="bibr" rid="bib40">Mohammed et al., 2016</xref>).</p><p>We previously reported that local antigen experienced T<sub>RM</sub> that have encountered cognate antigen in the skin are better able to persist in the epidermis than bystander T<sub>RM</sub> that have not encountered antigen in the skin when active TGFβ is limited, despite the fact that both groups of cells had prior activation within the lymph node (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>). This is evident when TGFβ activation is experimentally reduced by small molecule inhibition of ⍺vβ6 and ⍺vβ8 and when established T<sub>RM</sub> compete with newly recruited T<sub>EFF</sub> cells for limiting amounts of TGFβ activation. In both instances, bystander T<sub>RM</sub> are preferentially lost from the epidermis, while local antigen experienced T<sub>RM</sub> persist. Thus, an encounter with antigen in the skin results in more fit T<sub>RM</sub> and represents a potential opportunity to preferentially enrich antigen-specific over bystander T<sub>RM</sub> cells during repeated challenges.</p><p>Herein, we delineate mechanisms of T<sub>RM</sub> homeostasis by demonstrating that within a population of endogenous T<sub>RM</sub>, antigen encounter in the skin is required for their full differentiation, whereas bystander T<sub>RM</sub> are maintained at an earlier developmental stage. We also find that local antigen experienced T<sub>RM</sub> have increased proliferative capacity during a recall response compared to bystander T<sub>RM</sub> that is dependent on affinity of antigen experienced in skin, thus providing an additional functional attribute defining T<sub>RM</sub> fitness. Finally, we show that expression of TGFβRIII by local antigen experienced T<sub>RM</sub> which can be induced following TCR ligation is required for epidermal persistence when active TGFβ is limiting.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Epidermal T<sub>RM</sub> are transcriptionally heterogeneous</title><p>The recruitment of effector CD8<sup>+</sup> T cells into mouse flank skin via a viral infection (e.g. Vaccinia virus) or through an inflammatory stimulus (e.g. ‘DNFB-pull’) results in comparable numbers of long-lived CD103<sup>+</sup> epidermal T<sub>RM</sub> and is independent of the presence or absence of cognate antigen in the skin (<xref ref-type="bibr" rid="bib32">Mackay et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Hirai et al., 2019</xref>; <xref ref-type="bibr" rid="bib13">Davies et al., 2017</xref>). This, however, has only been demonstrated using HSV-specific (gBT-I) or OVA-specific (OT-I) TCR transgenic T cells. To determine if endogenous polyclonal CD8<sup>+</sup> T cells share this phenotype, we employed a dual VV infection ‘DNFB-pull’ model. Cohorts of wild-type C57BL/6 mice were infected on the left flank with VV by skin scarification (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The infection expanded CD8<sup>+</sup> effectors specific for VV antigens, which were then recruited into the left flank in response to the ongoing infection-induced inflammation. DNFB is applied to the right flank 5 days post-infection to recruit into the skin circulating CD8 effectors expanded by infection. Mice were then rested for 50+ days to allow for the formation of T<sub>RM</sub>. We have previously found that evaluation of T<sub>RM</sub> numbers in the epidermis by flow cytometry is much less accurate than direct immunofluorescent visualization (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>). Evaluation of whole-mounted epidermal sheets stained with anti-CD8 revealed comparable numbers of CD8<sup>+</sup> T cells at the VV-infected (left flank) and DNFB-treated (right flank) sites (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). Expression of CD103 on T<sub>RM</sub> as evaluated by flow cytometry was also similar at both sites (<xref ref-type="fig" rid="fig1">Figure 1D</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). To evaluate the frequency of antigen-specific T cells at each site, skin from a separate cohort was examined by flow cytometry using the B8R tetramer which recognizes an immunodominant epitope of VV in H2-K<sup>b</sup> (<xref ref-type="bibr" rid="bib41">Moutaftsi et al., 2006</xref>). We observed equivalent numbers of B8R<sup>+</sup> T<sub>RM</sub> at the VV-infected and DNFB-treated sites (<xref ref-type="fig" rid="fig1">Figure 1E and F</xref>). From these data, we conclude that polyclonal CD8 T cells form epidermal T<sub>RM</sub> with comparable efficiency when recruited into the skin by viral infection or sterile inflammation and that the presence or absence of cognate antigen in the skin has no effect on the number or frequency of antigen-specific T<sub>RM</sub>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Epidermal T<sub>RM</sub> are transcriptionally heterogeneous.</title><p>(<bold>A</bold>) Experimental design. Mice were treated with vaccinia virus infection by skin scarification on the left flank on day 0, and then on day 5 post-infection, the right flank was painted with 0.15% DNFB. On day 56, flanks were harvested for either epidermal whole mount, flow cytometry, or cells were sorted for scRNA-seq. (<bold>B</bold>) Representative images and (<bold>C</bold>) quantification of epidermal whole mounts of VV and DNFB treated flanks harvested on day 50 post infection stained for CD8a. (<bold>D</bold>) Representative flow plots gated on CD45<sup>+</sup> CD3<sup>+</sup> CD8<sup>+</sup> CD90.2<sup>+</sup> cells isolated from VV or DNFB treated flanks. (<bold>E</bold>) Representative flow plots and (<bold>F</bold>) quantification of B8R tetramer binding of CD103+ T<sub>RM</sub> gated as in (<bold>D</bold>) isolated from VV or DNFB treated flanks. (<bold>G</bold>) The integrated Minimal-Distorted Embedding of all 96 experiments from the ImmgenT consortium with annotated clusters. (<bold>H</bold>) Minimal-Distorted embedding visualization of transcriptional clusters of skin T<sub>RM</sub> projected over the ImmgenT dataset. (<bold>I</bold>) The percentage of cells in each transcriptional cluster found in VV or DNFB treated sites. Each symbol represents paired data from the same individual animal (<bold>C, F</bold>). Data shown to be nonsignificant by paired Student’s t-tests (<bold>C, F</bold>). Data are representative of 3 separate experiments. Scale bar in (<bold>B</bold>) represents 50 µm. Panel A was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/i3asce6">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Flow cytometric and gene expression analysis of the T<sub>RM</sub> used in the Immgen T scRNA-seq dataset.</title><p>(<bold>A</bold>) Quantification of percent CD103<sup>+</sup> T cells from VV and DNFB treated flanks, gated on live CD45.2<sup>+</sup>CD8<sup>+</sup>CD90.2<sup>+</sup>. Each bar represents the mean +/- SEM for n=6 animals. (<bold>B</bold>) Gating strategy for skin single-cell RNA-seq. (<bold>C</bold>) Flow plots of CD69 and CD103 expression of VV and DNFB treated flanks for single-cell RNA-seq gated as in (<bold>B</bold>). (<bold>D</bold>) Heatmap showing the top 10 DEG per cluster when compared with each other, calculated by FindAllMarkers of Seurat V2, percent expressed &gt;0.02, Log2foldchange &gt;2.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Although T<sub>RM</sub> efficiently populate the epidermis independently of cutaneous cognate antigen, we have previously demonstrated that T<sub>RM</sub> that form at skin sites containing cognate antigen are functionally distinct from bystander T<sub>RM</sub> that form in its absence (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>). To analyze potential transcriptional differences between local antigen experienced and bystander T<sub>RM</sub>, we performed single-cell RNA-seq in collaboration with the ImmgenT consortium (<xref ref-type="bibr" rid="bib68">Zemmour et al., 2022</xref>). The consortium consists of multiple groups that isolated populations of murine T cells from multiple tissues and contexts and then subjected them to single-cell RNA-seq (<xref ref-type="bibr" rid="bib68">Zemmour et al., 2022</xref>)(see Methods). 627,692 mature T cells from 80 different experiments and 703 samples were integrated and batch-corrected using totalVI (<xref ref-type="bibr" rid="bib27">Korsunsky et al., 2019</xref>) (see Methods). Cells were projected in two dimensions using Minimal-Distorted Embedding (see Methods), revealing the expected transcriptional clustering of distinct types of T cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). As part of the consortium, we isolated cells from the flanks of rested (&gt;65 days) VV-infected or DNFB-treated flank skin by enzymatic digestion. Cells were pooled from 10 mice and purified based on expression of CD90 and CD8 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). As expected, most cells expressed CD69 and CD103 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Skin cells from each group and naïve spleen cells were hash tagged and analyzed by single-cell RNA-seq. Analysis of transcripts revealed a total of 6 clusters (0–5) which are shown overlayed on the complete ImmgenT cell embedding (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). As expected, most cells clustered with CD8⍺β T cells (<xref ref-type="fig" rid="fig1">Figure 1G</xref>, black). There was, however, a high degree of heterogeneity, and some possibly contaminating cells fell outside of this region. A comparison of the relative frequency of cells in each of the clusters (0–5) isolated from the VV or DNFB sites revealed a strong enrichment of cluster 3 in the VV group and of clusters 0 and 2 in the DNFB group (<xref ref-type="fig" rid="fig1">Figure 1I</xref>, magenta). This suggested that cluster 3 cells were manifesting a distinct transcriptional state likely induced by antigen encounter in the skin.</p></sec><sec id="s2-2"><title>Cutaneous antigen is required for complete T<sub>RM</sub> differentiation</title><p>To test the hypothesis that cells in cluster 3 could be T<sub>RM</sub> that have encountered antigen in the skin during development, we performed signature score enrichment analysis comparing the transcriptional profile of our cells to published core genes of well-defined CD8 T cell states. Signature scores were calculated based on normalized differential gene expression compared to core genes of T<sub>RM</sub> generated by acute infection models (GSE47045), activated T cells (T<sub>ACT</sub>, GSE10239), circulating memory T cells (T<sub>MEM</sub>, GSE41867), and exhausted T cells (T<sub>EX</sub>, GS41867) (<xref ref-type="bibr" rid="bib24">Jaiswal et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Sarkar et al., 2008</xref>; <xref ref-type="bibr" rid="bib14">Doering et al., 2012</xref>). Notably, cells in cluster 3 showed enriched expression of T<sub>RM</sub> core genes compared to all other clusters (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We performed a similar analysis using pseudo-bulk analysis of all cells isolated from the VV or DNFB sites. Consistent with the enrichment of cluster 3 in cells from the VV site, we found a strong enrichment of T<sub>RM</sub> core genes in the VV group (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). These data suggest that cells in cluster 3 isolated from the VV site represent fully differentiated T<sub>RM</sub>.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cutaneous antigen is required for complete T<sub>RM</sub> differentiation.</title><p>(<bold>A</bold>) Signature score analysis of skin T cell clusters calculating the enrichment for previously published T cell state gene sets (N=naïve). Signature score = Mean (average upgenes z-scores) - Mean(average downgenes z-scores). *** <italic>P</italic>&lt;0.001 by Dunnett’s multiple comparisons of cluster 3 to all other clusters. (<bold>B</bold>) Pseudobulk analysis comparing signature scores of cells isolated from VV and DNFB sites as in (<bold>A</bold>). ** <italic>P</italic>&lt;0.01 and *** <italic>P</italic>&lt;0.001 by paired Student’s t-tests. (<bold>C</bold>) Signature score analysis of individual clusters or (<bold>D</bold>) cells isolated from VV and DNFB sites calculating the enrichment for compared to epidermal T<sub>RM</sub> isolated at the indicated day post infection. ***<italic>P</italic>&lt;0.001 by Dunnett’s multiple comparison test of cluster 3 to all other clusters in (<bold>C</bold>). * <italic>P</italic>&lt;0.05, ** <italic>P</italic>&lt;0.01, **** <italic>P</italic>&lt;0.0001 by paired Student’s t-tests in (<bold>D</bold>) Gray line represents a randomized control generated by the average enrichment of each group compared to a randomly generated gene set of an equal number of probes. Datapoints and error bars represent mean and 95% confidence interval of the relative enrichment of each set of DEGs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig2-v1.tif"/></fig><p>To further test the hypothesis that cluster 3 represents fully differentiated T<sub>RM</sub>, we performed signature score enrichment analysis of clusters 0–5 against a dataset of skin T cells isolated at different times following skin VV infection (GSE79805) (<xref ref-type="bibr" rid="bib45">Pan et al., 2017</xref>). Cells from clusters 0, 2 and 3 showed similar signature scores in comparison with skin T cells up to day 5 post-infection; however, clusters 0 and 2 then plateaued suggesting a lack of continued differentiation (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In contrast, cluster 3 transcripts scored higher at later time points in T<sub>RM</sub> differentiation. Signature scores for cells isolated from the DNFB and VV sites were similar at early time points but diverged at later time points with increased scores observed in cells from the VV site (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Taken together, these data suggest that T<sub>RM</sub> isolated from skin sites where they can encounter cognate antigen are transcriptionally more fully differentiated T<sub>RM</sub> while bystander T<sub>RM</sub> isolated from a site lacking cognate antigen remain in a less differentiated state.</p></sec><sec id="s2-3"><title>Local antigen experienced T<sub>RM</sub> have improved expansion in a recall response</title><p>Analysis of the 10 highest differentially expressed genes (DEGs) in cluster 3 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>) showed increased expression of genes associated with T cell activation, including <italic>Dusp1</italic> and <italic>Nr4a1</italic> as well as the AP-1 family members J<italic>unb</italic> and <italic>Fos</italic> (<xref ref-type="bibr" rid="bib46">Papavassiliou and Musti, 2020</xref>; <xref ref-type="bibr" rid="bib44">Owens and Keyse, 2007</xref>; <xref ref-type="bibr" rid="bib17">Gazon et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Schnoegl et al., 2023</xref>; <xref ref-type="bibr" rid="bib60">Sun et al., 2021</xref>). Given the importance of AP-1 family members in T cell proliferation and differentiation, we next tested whether this corresponded to functional differences in T<sub>RM</sub> activity (<xref ref-type="bibr" rid="bib53">Schnoegl et al., 2023</xref>; <xref ref-type="bibr" rid="bib4">Atsaves et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Shaulian and Karin, 2002</xref>; <xref ref-type="bibr" rid="bib10">Buquicchio et al., 2024</xref>). An important functional property of T<sub>RM</sub> is their capacity to rapidly expand following re-encounter with cognate antigen (<xref ref-type="bibr" rid="bib61">Szabo et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Schenkel and Masopust, 2014</xref>). To determine whether local antigen experienced and bystander T<sub>RM</sub> have different recall responses, we repeated our dual VV infection and DNFB ‘pull’ model in combination with an OT-I adoptive transfer model to allow for antigen recall using the SIINFEKL peptide. CD90.1<sup>+</sup> OT-I cells were adoptively transferred into naïve C57BL/6 mice followed by infection with a vaccinia virus expressing SIINFEKL peptide, OVA<sub>257-264</sub> (VV-OVA) on the left flank. On day 5 post-infection, the right flank was treated with DNFB to recruit expanded OT-I effectors to the site (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). On day 50+ after infection, topical SIINFEKL peptide or control PBS was painted on both flanks in a single application (1° recall). The total number of OT-I cells in the epidermis 6 days later was determined by immunofluorescent microscopic evaluation of the CD90.1 congenic marker in epidermal whole mounts (<xref ref-type="fig" rid="fig3">Figure 3B–C</xref>). Restimulation with peptide led to an expansion of T<sub>RM</sub> at both sites compared to PBS-treated controls. Notably, local antigen experienced OT-I T<sub>RM</sub> cells in the VV-OVA treated flanks expanded to a larger extent compared to bystander T<sub>RM</sub> in DNFB treated flanks. To inhibit potential recruitment of circulating effector OT-I cells, we repeated these experiments administering FTY720 to block migration of T cells from lymph node or titrated anti-Thy1.1 antibody to ablate circulating OT-I but not T<sub>RM</sub> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Both methods successfully depleted OT-I from the blood (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–D</xref>), without affecting T<sub>RM</sub> in the skin (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Administration of FTY720 (<xref ref-type="fig" rid="fig3">Figure 3E–F</xref>) or anti-Thy1.1 treatment (<xref ref-type="fig" rid="fig3">Figure 3G</xref>) had no effect on the number of OT-I T<sub>RM</sub> in the epidermis after a 1° recall response and local antigen experienced T<sub>RM</sub> from the VV-OVA treated flank still expanded to a greater degree than bystander T<sub>RM</sub> from the DNFB treated flank. Thus, the increased number of epidermal OT-I at the local antigen experienced VV site during a 1° recall does not appear to result from recruitment of circulating cells.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Local antigen experienced T<sub>RM</sub> have improved expansion in a recall response.</title><p>(<bold>A</bold>) Experimental design. Mice were adoptively transferred with Thy1.1<sup>+</sup> OT-I T cells on day –1, then infected with OVA-expressing vaccinia virus by scarification on the left flank on day 0. On day 5 post-infection, the right flank was painted with 0.15% DNFB. On day 50, a primary recall response with SIINFEKL peptide in acetone and olive oil was painted on both flanks and harvested on day 56. In some cohorts, mice were allowed to rest for an additional 120 days and then treated with topical SIINFEKL peptide again on day 176 and harvested on day 182. (<bold>B</bold>) Representative images and (<bold>C</bold>) quantification of epidermal whole mounts isolated from VV-OVA and DNFB treated flanks stained for anti-Thy1.1 (n=10 animals). (<bold>D</bold>) Experimental design. Mice were treated as in (<bold>A</bold>), but for 6 days prior to SIINFEKL treatment, they were given either i.p. FTY720, i.p. PBS, i.v. titrated anti-Thy1.1 or i.v. isotype control. (<bold>E</bold>) Representative epidermal whole mount images and (<bold>F</bold>) quantification of skin from VV-OVA treated flanks on day 6 of a primary recall response treated with either FTY720 or PBS. (<bold>G</bold>) Quantification of total Thy1.1 OT-I cells in epidermal whole mounts on day 6 after a primary recall response in mice treated with either isotype or anti-Thy1.1 depleting antibody. Each symbol represents paired data from an individual same animal (<bold>F, G</bold>). Data are representative of 3 independent experiments. *<italic>P</italic>&lt;0.05 by paired Student’s t-tests. Unpaired Student’s t-tests between FTY720 treated (<bold>F</bold>) or Anti-Thy1.1 treated (<bold>G</bold>) flanks and PBS treated flanks shows non-significance for both VV-OVA and DNFB. Scale bar represents 50 µm (<bold>B, F</bold>). Each symbol represents the mean +/- SEM (<bold>C</bold>). Panel A and D were created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/uv2ugq3">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>FTY720 and anti-Thy1.1 deplete circulating OT-I cells withouth affecting the epidermis.</title><p>(<bold>A</bold>) Representative flow plots of blood from Thy1.1 OT-I adoptive transferred mice after 6 days of vehicle or FTY720 treatment, gated on live CD45<sup>+</sup>. (<bold>B</bold>) Quantification of total Thy1.1 OT-I in blood after FTY720 treatment, gated as in (<bold>A</bold>). Each bar represents the mean +/– SEM for n=6 animals. (<bold>C</bold>) Representative flow plots of blood of CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> cells after isotype or Thy1.1 depleting antibody treatment. (<bold>D</bold>) Quantification of Thy1.1 OT-I in blood before and after isotype or anti-Thy1.1 depleting antibody treatment, gated as in (<bold>C</bold>). (<bold>E</bold>) Representative epidermal whole mount of Thy1.1<sup>+</sup> cells in the epidermis at steady state of VV-OVA or DNFB treated flanks after 6 days of isotype or anti-Thy1.1 depleting antibody treatment. Each symbol represents data from an individual animal. Data is representative of three separate experiments.*<italic>p</italic>&lt;0.05 by unpaired Student’s t-tests. Scale bar represents 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Finally, to determine whether increased expansion by local antigen experienced T<sub>RM</sub> persists with multiple rounds of stimulation, we repeated this experiment but allowed mice to rest for 120 days after the 1° recall response. The number of T<sub>RM</sub> at both the VV-OVA and DNFB sites contracted down to equivalent numbers that were increased compared to PBS-treated, control mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Mice were then given a 2° recall by a second application of peptide at day +176. The number of T<sub>RM</sub> expanded but T<sub>RM</sub> at the VV-OVA site increased by a larger amount than T<sub>RM</sub> at the DNFB site (<xref ref-type="fig" rid="fig3">Figure 3B–C</xref>). Based on these data, we conclude that T<sub>RM</sub> encountering antigen in the skin during development expand more efficiently in response to antigen re-encounter and this phenotype persists long-term with subsequent antigen encounters.</p></sec><sec id="s2-4"><title>Local antigen experienced T<sub>RM</sub> exhibit increased proliferation during a recall response</title><p>We next hypothesized that the increased expansion of local antigen experienced T<sub>RM</sub> during a recall response resulted from increased proliferation. To test this, as above, WT mice adoptively transferred with OT-I cells were infected with VV-OVA on the left flank and DNFB on the right flank 5 days later. After at least 50 days of rest, both sides were painted with topical SIINFEKL peptide and mice were administered 2 mg of BrdU i.p. daily (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Epidermal sheets for immunofluorescent visualization were harvested 2 days later. We noted a clear increase in the percent and total number of dividing cells as well as the total number of OT-I T cells in the epidermis at the VV-OVA site compared with the DNFB site (<xref ref-type="fig" rid="fig4">Figure 4B–D</xref>). Similar results were obtained by flow cytometry, with an increase in the percentage of BrdU<sup>+</sup> in T<sub>RM</sub> isolated from the VV-OVA site (<xref ref-type="fig" rid="fig4">Figure 4E–G</xref>). Staining for Annexin V was equivalent in both groups, suggesting that an altered rate of apoptosis does not contribute to the observed changes in expansion (<xref ref-type="fig" rid="fig4">Figure 4H–I</xref>). In sum, local antigen experienced T<sub>RM</sub> show augmented proliferation during an antigen recall response compared with bystander T<sub>RM</sub>. Moreover, an enhanced proliferative capacity following antigen restimulation can now be added to other parameters of T<sub>RM</sub> fitness, including enhanced epidermal persistence when active TGFβ is limited.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Local antigen experienced T<sub>RM</sub> have increased proliferation during a recall response.</title><p>(<bold>A</bold>) Experimental scheme. (<bold>B</bold>) Representative images of epidermal whole mounts of VV-OVA or DNFB treated flanks on day 2 of a recall response. Arrows highlight cell doublets. (<bold>C</bold>) Quantification showing percent OT-I cells that are dividing in epidermal whole mounts on day 2 after primary recall response, and (<bold>D</bold>) total number of dividing OT-I cells. (<bold>E</bold>) Representative flow cytometric plots and (<bold>F</bold>) quantification showing BrdU incorporation in gated CD45<sup>+</sup> CD8<sup>+</sup> CD90.1<sup>+</sup> CD103<sup>+</sup> CD69<sup>+</sup> cells isolates from VV-OVA or DNFB treated flanks. (<bold>G</bold>) Quantification of total numbers BrdU<sup>+</sup> OT-I cells combining OT-I numbers with percentage of BrdU incorporation in (<bold>F</bold>). (<bold>H</bold>) Representative histograms and (<bold>I</bold>) quantification of Annexin V expression in OT-I cells isolated from VV-OVA or DNFB treated flanks or OT-I cells heat-treated at 60°C for 1 hr (HK). Data are representative of three separate experiments. *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01 by Student's paired t-tests (<bold>C</bold>, <bold>D</bold>,<bold> F</bold> and <bold>G</bold>) or Dunnett’s test (<bold>I</bold>). Scale bar represents 50 µm. Panel A was created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/dprrajw">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig4-v1.tif"/></fig></sec><sec id="s2-5"><title>T<sub>RM</sub> fitness depends on TCR signal strength</title><p>We next hypothesized that the strength of TCR signal provided in the skin during T<sub>RM</sub> differentiation should correlate with T<sub>RM</sub> phenotype at late time points. To generate T<sub>RM</sub> with a range of local antigen encounter signal strengths, we wanted to expose newly-recruited T cells to either topical SIINFEKL peptide (N4), or a topical altered peptide ligand (APL) SIYNFEKL (Y3) that has ¼ the avidity for the TCR receptor (<xref ref-type="bibr" rid="bib67">Zehn et al., 2009</xref>). We hypothesized that encountering an APL would induce an intermediate functional phenotype between full-strength SIINFEKL and no local antigen encounter. To test this hypothesis, WT mice were adoptively transferred with OT-I cells, then infected with VV-OVA on the left flank and 5 days later were challenged with DNFB on the right flank (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). One day later, the DNFB site was painted with PBS, SII<bold>N</bold>FEKL (N4), or an APL SI<bold>Y</bold>NFEKL (Y3). After 50+ days of rest, all mice were challenged in a 1° recall response with topical N4 or control PBS at the DNFB sides (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Epidermal sheets for immunofluorescence were harvested 6 days later. As expected, mice restimulated with PBS showed equivalent numbers of T<sub>RM</sub> regardless of which peptide was provided during development (<xref ref-type="fig" rid="fig5">Figure 5B–C</xref>). Following a 1° recall response, T<sub>RM</sub> exposed to N4 (DNFB +N4) expanded to a level equivalent to T<sub>RM</sub> from the VV-OVA site. In contrast, T<sub>RM</sub> exposed to Y3 (DNFB +Y3) showed a degree of expansion that was intermediate compared to T<sub>RM</sub> that did not experience antigen in the skin (DNFB +PBS) and those that experienced SIINFEKL (DNFB +N4). Thus, the strength of TCR engagement determines the fitness of T<sub>RM</sub> based on their capacity to expand during a 1° recall response.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>T<sub>RM</sub> fitness depends on TCR signal strength.</title><p>(<bold>A</bold>) Experimental scheme. Local antigen experienced and bystander T<sub>RM</sub> were generated and restimulated as previously described, but on the DNFB-treated flanks, altered peptide ligand variants of SIINFEKL were topically applied to the skin 1 day after recruitment to the skin. (<bold>B</bold>) Representative images and (<bold>C</bold>) quantification of epidermal whole mounts (CD90.1 cyan) of VV-OVA and DNFB+ APL treated flanks, at steady state (no recall) or 6 days post-recall response. Each symbol represents data from an individual animal. Data are representative of 5 independent experiments. *<italic>p</italic>&lt;0.05 by unpaired Student’s t-tests. Scale bar, 50 µm. Panel A created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/vrp9m3x">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title>Local antigen experienced T<sub>RM</sub> have improved persistence mediated by TGFßRIII</title><p>A feature of local antigen experienced T<sub>RM</sub> is that they are better able to persist in the epidermis than bystanders when levels of activated TGFβ are limited, either artificially or during competition with newly recruited T<sub>EFF</sub> (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>). We have previously found that expression of the canonical TGFβ receptors, <italic>Tgfbr1</italic> and <italic>Tgfbr2</italic> have equivalent expression in local antigen experienced and bystander T<sub>RM</sub> (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>). However, there is a third TGFβ receptor, TGFβRIII, that lacks a signaling component but functions as a reservoir of ligand for TGFβ, increasing avidity of the TGFβ receptor (<xref ref-type="bibr" rid="bib39">Miyazono, 1997</xref>; <xref ref-type="bibr" rid="bib20">Heldin and Moustakas, 2016</xref>). Notably, expression of TGFβRIII has been reported to increase in T cells following TCR ligation (<xref ref-type="bibr" rid="bib43">Ortega-Francisco et al., 2017</xref>). This was confirmed in vitro with anti-CD3 anti-CD28 stimulated OT-I splenocytes (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We also observed increased expression of TGFβRIII in vivo, comparing local antigen experienced OT-I T<sub>RM</sub> with bystanders (<xref ref-type="fig" rid="fig6">Figure 6B–C</xref>). Based on this data, we hypothesized that increased expression of TGFβRIII on antigen experienced T<sub>RM</sub> could explain their capacity to maintain epidermal residence when available TGFβ is limiting.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Local <italic>antigen experienced T<sub>RM</sub> have improved persistence mediated by TGFßRIII</italic>.</title><p>(<bold>A</bold>) Representative flow cytometric plots of TGFßRIII staining of Thy1.1<sup>+</sup> OT-I cells stimulated in vitro for 48 hr with PBS or anti-CD3 anti-CD28. (<bold>B</bold>) Representative histograms showing TGFßRIII expression in CD45<sup>+</sup> CD3<sup>+</sup> CD8<sup>+</sup> CD90.1<sup>+</sup> gated OT-I cells isolated from VV-OVA, DNFB or untreated flanks at least 50 days post infection. (<bold>C</bold>) Quantification of (<bold>B</bold>). (<bold>D</bold>) Schematic demonstrating genetics of Tgfbr3<sup>WT</sup> and Tgfbr3<sup>ΔCD8</sup> mice. (<bold>E</bold>) Representative histogram and (<bold>F</bold>) quantification of TGFßRIII expression in huNGFR<sup>-</sup> or huNGFR<sup>+</sup> Tgfbr3<sup>∆CD8</sup> T cells harvested 5 days following i.p. treatment with tamoxifen then stimulated in vitro for 48 hr with anti-CD3 and anti-CD28. (<bold>G</bold>) Experimental scheme. (<bold>H</bold>) Representative histogram of CD45.2+CD3+CD8+CD90.1+OT I cells isolated from LNs after tamoxifen treatment demonstrating transformation efficiency. (<bold>I</bold>) Representative epidermal whole mounts showing Thy1.1 staining (green), huNGFR staining (red) or merge (yellow) of VV-OVA or DNFB treated flanks from mice adoptively transferred with either Tgfbr3<sup>WT</sup> or Tgfbr3<sup>∆CD8</sup> cells, treated with tamoxifen i.p., and then given either PBS or i.p. CWHM12 for 10 days. Hair follicles in the sample present as long yellow streaks. (<bold>J</bold>) Quantification of total huNGFR<sup>+</sup> Thy1.1<sup>+</sup> OT-I in (<bold>I</bold>). Each symbol represents data from an individual animal. Black lines represent group means. Data is representative of 3 independent experiments. *<italic>P</italic>&lt;0.05 by Dunnett’s test (<bold>C</bold>) or paired Student’s t-tests (<bold>F</bold>) and (<bold>J</bold>). Unpaired Student’s t-tests between Tgfbr3<sup>WT</sup> and Tgfbr3<sup>∆CD8</sup> vehicle-treated groups show non-significance for both VV-OVA and DNFB treated flanks. Scale bar represents 50 µm. Panel D and G were created with <ext-link ext-link-type="uri" xlink:href="https://BioRender.com/q4gomes">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-fig6-v1.tif"/></fig><p>To test this, we generated OT-I Thy1.1<sup>+</sup> E8i-cre<sup>ERT2</sup> huNGFR <italic>Tgfbr3</italic><sup>fl/fl</sup> (Tgfbr3<sup>∆CD8</sup>) mice which allow for inducible ablation of <italic>Tgfbr3</italic> from T<sub>RM</sub> as well as control OT-I Thy1.1<sup>+</sup> E8i-cre<sup>ERT2</sup> huNGFR <italic>Tgfbr3</italic><sup>WT/WT</sup> (Tgfbr3<sup>WT</sup>) mice (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). To validate these mice, Tgfbr3<sup>∆CD8</sup> mice were treated with 0.05 mg/g tamoxifen i.p. for 5 days. CD8<sup>+</sup> T cells from tamoxifen-treated Tgfbr3<sup>∆CD8</sup> mice were then isolated from spleen and lymph nodes and cultured for 2 days with anti-CD3 anti-CD28. Cells were evaluated by flow cytometry for expression of TGFβRIII and huNGFR, an indicator of successful induction of cre-mediated excision by tamoxifen. In the huNGFR-negative population where cre was not activated, approximately 50% of the cells expressed TGFβRIII (<xref ref-type="fig" rid="fig6">Figure 6E–F</xref>). In contrast, TGFβRIII was largely absent from cells co-expressing huNGFR, indicative of efficient ablation of <italic>Tgfbr3</italic>.</p><p>To ablate TGFβRIII from T<sub>RM</sub> once they have fully differentiated in the epidermis, we next adoptively transferred CD8<sup>+</sup> T cells isolated from either Tgfbr3<sup>WT</sup> or Tgfbr3<sup>∆CD8</sup> mice into naïve WT mice followed by skin VV-OVA infection on the left flank. On day 5 post-infection, the right flank was treated with DNFB. After at least 50 days of rest to allow for T<sub>RM</sub> formation, both cohorts were treated daily with 0.05 mg/g tamoxifen i.p. to transform approximately 50% of adoptively transferred cells, generating populations of both control huNGFR negative and huNGFR positive OT-I cells. To test the effects of TGFβRIII ablation, TGFβ activation was inhibited for 10 days by i.p. administration of CWHM12, a small molecule inhibitor of integrins ⍺vβ6 and ⍺vβ8 (<xref ref-type="fig" rid="fig6">Figure 6G–H</xref>). Analysis of epidermal whole mounts by immunofluorescence revealed that blockade of TGFβ activation reduced the number of bystander Tgfbr3<sup>WT</sup> T<sub>RM</sub> at the DNFB site, but not local antigen experienced T<sub>RM</sub> at the VV-OVA site, consistent with our earlier results (<xref ref-type="fig" rid="fig6">Figure 6I–J</xref>). In contrast, local antigen experienced huNGFR<sup>+</sup> Tgfbr3<sup>∆CD8</sup> T<sub>RM</sub> from the VV-OVA site that lack TGFβRIII were efficiently depleted from the epidermis by CWHM12 treatment. The depletion of bystander huNGFR<sup>+</sup> Tgfbr3<sup>∆CD8</sup> T<sub>RM</sub> at the DNFB site was augmented. Notably, numbers of Tgfbr3<sup>∆CD8</sup> T<sub>RM</sub> in cohorts treated with vehicle did not induce a statistically significant reduction in steady-state T<sub>RM</sub>, indicating that loss of TGFβRIII is not an absolute requirement for T<sub>RM</sub> epidermal residence in the steady state. Thus, expression of TGFβRIII by local antigen experienced T<sub>RM</sub> which is downstream of TCR ligation is required for their capacity to remain in the epidermis when activated TGFβ is limiting.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Herein, we have demonstrated that the increased capacity of local antigen experienced T<sub>RM</sub> to persist in the epidermis when levels of TGFβ are limited is mediated by increased expression of TGFβRIII. We also show that local antigen experienced T<sub>RM</sub> have increased proliferative capacity during repeated antigen recalls. In addition, the increased proliferative capacity was directly correlated with the strength of TCR stimulation during T<sub>RM</sub> development. Finally, we found that local antigen experienced T<sub>RM</sub> appear more transcriptionally related to fully differentiated T<sub>RM</sub>. Taken together, these data support a model in which TCR engagement by cognate antigen in the skin is a required final step in T<sub>RM</sub> differentiation resulting in their increased fitness exemplified by increased proliferative capacity and the ability to persist in the epidermis when active TGFβ is limited.</p><p>We propose that the augmented fitness of local antigen experienced T<sub>RM</sub> represents a mechanism to enrich for high avidity TCR clones in the epidermis. Skin inflammation recruits T<sub>EFF</sub> into the skin, some of which develop into T<sub>RM</sub>. In the absence of competition with pre-existing T<sub>RM</sub>, T<sub>RM</sub> form comparably in the presence or absence of cognate antigen. Thus, we found equivalent numbers of bystander T<sub>RM</sub> at the DNFB and local antigen experienced T<sub>RM</sub> at the VV sites with both TCR transgenic and endogenous T cells. In contrast, when new T<sub>EFF</sub> are recruited into sites with pre-existing T<sub>RM</sub>, there is clonal competition for limited amounts of active TGFβ, resulting in enrichment of fitter, local antigen experienced T<sub>RM</sub> (<xref ref-type="bibr" rid="bib23">Hirai et al., 2021</xref>). We now find that this enrichment likely results from 2 different competitive advantages. First, antigen encounter in the skin results in increased expression of TGFβRIII, which increases TGFβ avidity for the signaling by the TGFβ receptor. Since TGFβ signaling is required for epidermal persistence, this would provide an advantage for local antigen experienced T<sub>RM</sub> over bystanders. Second, local antigen experienced T<sub>RM</sub> have increased proliferation when re-encountering antigen in the epidermis. Following repeated challenges which would be expected outside of SPF conditions, the combination of improved expansion and persistence would work together to enrich for high avidity clones, thereby shaping the epidermal CD8<sup>+</sup> T cell memory pool. Recently, it has been observed that T<sub>RM</sub> can contribute significantly to the pool of circulating memory cells (<xref ref-type="bibr" rid="bib56">Steinert et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Beura et al., 2018b</xref>; <xref ref-type="bibr" rid="bib16">Fonseca et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Wijeyesinghe et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Behr et al., 2020</xref>). Thus, mechanisms augmenting epidermal T<sub>RM</sub> fitness that shape the pool of epidermal T<sub>RM</sub> may also affect the pool of systemic memory cells and represent an example of extra-thymic clonal section.</p><p>When T<sub>RM</sub> were challenged in a primary antigen recall response, we noted that local antigen experienced T<sub>RM</sub> expanded to a greater extent than bystanders. This expansion resulted from increased in-situ proliferation with minimal contribution from newly recruited T<sub>EFF</sub>, consistent with prior reports (<xref ref-type="bibr" rid="bib47">Park et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Beura et al., 2018a</xref>; <xref ref-type="bibr" rid="bib12">Çuburu et al., 2012</xref>). Interestingly, a similar phenomenon occurred following a second encounter with antigen. This indicates that an encounter with peptide at a late time point after T<sub>RM</sub> differentiation (&gt;50 days) is insufficient to convert bystander T<sub>RM</sub> into local antigen experienced T<sub>RM</sub>. Thus, there appears to be a window during T<sub>RM</sub> development when TCR engagement can allow for full differentiation. We also observed after a single recall response that T<sub>RM</sub> contracted to an elevated baseline, suggesting an increase in the epidermal niche. We speculate this may result from a reduced T cell intrinsic requirement for survival and/or homeostatic proliferation factors, such as IL-7 or IL-15 or increased expression of these factors by keratinocytes (<xref ref-type="bibr" rid="bib50">Richmond et al., 2018</xref>; <xref ref-type="bibr" rid="bib1">Adachi et al., 2015</xref>). Altered sensitivity or availability of TGFβ is unlikely to explain the increased niche size, as this would be predicted to vary between local antigen experienced and bystander.</p><p>Transcriptional analysis of T<sub>RM</sub> isolated from the small intestine have revealed intra-organ heterogeneity, with unique transcriptional populations arising early during T<sub>RM</sub> development (<xref ref-type="bibr" rid="bib38">Milner et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Kurd et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Fitz Patrick et al., 2021</xref>). This aligns well with our identification of 6 distinct transcriptional clusters of epidermal T<sub>RM</sub>. Cluster 3 appears to represent fully differentiated T<sub>RM</sub> based on comparison with other T<sub>RM</sub> datasets. In addition, cluster 3 cells more highly expressed the activation and proliferation-associated genes <italic>Junb, Fos</italic> and <italic>Dusp1</italic> as well as <italic>Nr4a1</italic>. Increased basal expression of the AP-1 family members <italic>Junb and Fos</italic> could contribute to the enhanced proliferation of antigen-experienced epidermal T<sub>RM</sub> during a recall response. Intriguingly, memory CD8 T cells lacking the transcription factor Zbtb20 manifest elevated expression of AP-1 family members and mount more robust antitumor responses (<xref ref-type="bibr" rid="bib19">Hao et al., 2024</xref>). The <italic>Nr4a1</italic> gene encodes for Nur77, which is induced by TCR signaling and its expression correlates with peptide avidity. Notably, Nur77 is required for T<sub>RM</sub> formation in the liver (<xref ref-type="bibr" rid="bib33">Mackay et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Mackay et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Aluwihare et al., 2009</xref>; <xref ref-type="bibr" rid="bib25">Jennings et al., 2020</xref>; <xref ref-type="bibr" rid="bib9">Boddupalli et al., 2016</xref>). Interestingly, cells in cluster 3 only accounted for 27% of T<sub>RM</sub> that had the opportunity to encounter their cognate antigen in the VV-treated flank. We speculate that not all clones at the VV site fully develop into fitter T<sub>RM</sub> due to lower TCR avidity or specificity to viral antigens only expressed early during infection, which would be absent once the clones arrived into skin.</p><p>In sum, TCR signaling during T<sub>RM</sub> differentiation represents a previously unappreciated final step in T<sub>RM</sub> differentiation. This results in fitter T<sub>RM</sub> with a lower requirement for TGFβ transactivation due to increased expression of TGFβRIII and enhanced proliferation in response to peptide stimulation. Moreover, the differing responses to altered peptide ligands indicate that the degree of fitness depends on TCR signal strength. Thus, polyclonal T<sub>RM</sub> likely develop into a spectrum of bystander to local antigen experienced cells based on TCR avidity. Though we have focused entirely on epidermal T cells, we suspect that these mechanisms may play a role in other epithelial tissues where residency is also dependent upon TGFβ. Additionally, we have solely investigated memory CD8<sup>+</sup> T cells after acute inflammation; the role of ongoing TCR-engagement during chronic antigen encounter remains unexplored.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>We generated Thy1.1<sup>+</sup><italic>Rag1</italic><sup>−/−</sup>OT-I mice by crossing OT-I mice with <italic>Rag1</italic><sup>−/−</sup> and Thy1.1 mice. E8I-<italic>cre</italic>ER<sup>T2</sup> and ROSA26.LSL.hNGFR reporter mice were developed by Dario A.A. Vignali (University of Pittsburgh) (<xref ref-type="bibr" rid="bib21">Hirai et al., 2019</xref>). E8I-<italic>cre</italic>ER<sup>T2</sup> mice and Thy1.1<sup>+</sup><italic>Rag1</italic><sup>-/-</sup>OT-I mice were crossed with ROSA26.LSL.hNGFR reporter mice to generate Tgfbr3<italic><sup>WT</sup></italic> mice and additionally with <italic>Tgfbr3</italic><sup>fl/fl</sup> mice to obtain Tgfbr3<sup>ΔCD8</sup> mice. <italic>Tgfbr3<sup>fl/fl</sup></italic> mice were developed by Herbert Y Lin (Program in Membrane Biology/Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts) (<xref ref-type="bibr" rid="bib30">Li et al., 2018</xref>). We used age- and sex-matched female mice that were between 6 and 12 weeks of age at the start of all experiments. All mice were maintained under specific-pathogen-free conditions and all animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee under the Animal Welfare Assurance Number D16-00118 (A3187-01).</p></sec><sec id="s4-2"><title>T<sub>RM</sub> cell models and blocking TGFβ activation treatments</title><p>Mice were infected by skin scarification (skin infection) with 3 × 10<sup>6</sup> plaque-forming units recombinant vaccinia virus expressing the SIINFEKL peptide of ovalbumin (VV-OVA), or vaccinia virus without recombinant peptide expression (VV). For skin scarification, 45 μL of VV-OVA or VV was applied to shaved left flank (4–5 cm<sup>2</sup>) and the skin were gently scratched 100 times with 27 G needle under anesthesia. VV or VV-OVA infected mice were further treated with 0.15% 1-Fluoro-2,4-dinitrobenzene (DNFB, D1529: Sigma-Aldrich) in 4:1 acetone: olive oil (O1514, Sigma-Aldrich) on the flank opposite the site of infection (40 μL) 5 days post infection. In some experiments, 4:1 acetone and olive oil was added to the stock solution of OVA<sub>257–264</sub> (SIINFEKL or SIYNFEKL, RP101611, Genscript/Fisher) in DMSO (D2650, Sigma-Aldrich) (10 mg/mL) for a final concentration of OVA<sub>257–264</sub> at 0.2 mg/mL and 50 μL was painted to the DNFB-treated skin 1 day after DNFB treatment.</p></sec><sec id="s4-3"><title>Recall response</title><p>50+days after VV-OVA infection. 4:1 acetone and olive oil was added to the stock solution of OVA<sub>257–264</sub> (SIINFEKL, RP101611, Genscript/Fisher) in DMSO (D2650, Sigma-Aldrich) (10 mg/mL) for a final concentration of OVA<sub>257–264</sub> at 0.2 mg/mL and 50 μL was painted to both flanks.</p></sec><sec id="s4-4"><title>CWHM12 treatments</title><p>For blocking TGFβ activation with a small molecule integrin inhibitor, compound CWHM12 (kindly provided by Indalo Therapeutics, Cambridge, MA) was solubilized in 100% DMSO. Further dilution to 50% DMSO was made in sterile 100% PBS and dosed to 100 mg per kg body weight per day delivered by i.p. injections once a day for 10 days.</p></sec><sec id="s4-5"><title>Adoptive transfers</title><p>OT-I cells were purified from spleen and lymph nodes by MojoSort Mouse CD8 T Cell Isolation Kit (48007, BioLegend) according to the manufacturer’s instructions and 1 × 10<sup>5</sup> OT-I cells were intravenously transferred in all experiments. All mice were allowed to rest for 1 day before further experimentation.</p></sec><sec id="s4-6"><title>Tamoxifen treatment</title><p>Tamoxifen (T5648; Sigma-Aldrich) was dissolved in 1/10th volume of 200 proof ethanol following incubation at 37°C for 15–30 min with 300 rpm shaking. Corn oil (C8267, Sigma-Aldrich) was added for a final concentration of Tamoxifen at 10 mg/ml and was administered to mice for 5 consecutive days by intraperitoneal injection at 0.05 mg per g body weight, in order to transform approximately 50% of adoptively transferred cells.</p></sec><sec id="s4-7"><title>BrdU treatment</title><p>BrdU (B5002, Sigma-Aldrich) was dissolved in sterile PBS. 2 mg in 200 uL of PBS was injected i.p. daily into each mouse for 2 consecutive days before harvest.</p></sec><sec id="s4-8"><title>Immunofluorescence of epidermis</title><p>Epidermal sheets were prepared as previously described (<xref ref-type="bibr" rid="bib40">Mohammed et al., 2016</xref>). Briefly, 2 square cm sections were harvested 2 cm distal from the mid-clavicular line for consistency, and then the epidermal side of shaved defatted flank skin was affixed to slides with double-sided adhesive (3M, St. Paul, MN). Slides were incubated in 10 mM EDTA in PBS for 90 min at 37°C, followed by physical removal of the dermis. The epidermal sheets were fixed in 4% PFA at RT for 15 min. The epidermal sheets were blocked with PBS containing 0.1% Tween-20, 2% BSA and 2% rat serum for 1 hr at RT before staining for 1 hour with antibodies at RT in PBS containing 0.1% Tween-20 and 0.5% BSA. The slides were mounted with ProLong Gold Antifade Mount with DNA stains DAPI (P36931, Thermofisher). Images were captured on a Keyence BZX800 fluorescent microscope (Keyence, Osaka, Japan). Analysis was performed using BZ-H4A Advanced Analysis Software (Keyence, Osaka, Japan). For the enumeration of cells, three images from distant sites randomly determined within an epidermal sheet from a mouse were counted (total 3 mm<sup>2</sup>) manually after image processing by Adobe Photoshop (version 6) and the average number per mm<sup>2</sup> epidermis was calculated as representative of the epidermal sheet. Anti-CD8α (53–6.7), Thy1.1 (OX-7) and huNGFR (ME20.4) were purchased from BioLegend.</p></sec><sec id="s4-9"><title>Depletion of circulation cells</title><p>For depletion of circulating memory OT-I cells, OT-I adoptive transfer VV-OVA and DNFB treated mice were injected i.p. with 0.3–1 μg anti-Thy1.1 (HIS51, ThermoFisher) in 200 μL PBS for 10 consecutive days. Depletion of OT-I T cells (&lt;0.5% of total CD8<sup>+</sup> T cells and &lt;1%) were confirmed by staining with anti-Thy1.1 (OX-7) using blood 3 days after depletion. For FTY720 treatment, OT-I adoptive transfer VV-OVA and DNFB-treated mice were injected i.p. with FTY720 (10006292, Fisher/Cayan Chemical) at 1 μg/g body weight in sterile PBS with 0.5% DMSO (D2650, Sigma-Aldrich) daily for 6 days. Depletion of circulating cells was confirmed with staining of anti-Thy1.1 (OX-7) and anti-CD8α (53–6.7) using blood 3 days after the end of treatment.</p></sec><sec id="s4-10"><title>Flow cytometry</title><p>Preparation of single cell suspension from skin, shaved skin was harvested, and fat tissues was removed by forceps mechanically. The skin was then mechanically digested with either scissors or a gentleMACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany), and then resuspended in RPMI 1640 media (Gibco, Grand Island, NY) containing 2.5 mg/ml Collagenase XI (9001-12-1, Sigma-Aldrich), 0.1 mg/ml DNase (04536282001, Sigma-Aldrich), 0.01 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (7365-45-9, Sigma-Aldrich), and 10% fetal bovine serum, followed by incubation in a shaking incubator for 30 min at 37°C. The resulting cell mesh was filtered through a 40-μm cell strainer (BD Biosciences, San Jose, CA). The single-cell suspension was then resuspended in 44% Percoll (89428-524, VWR) in RPMI and layered over 67% Percoll in PBS. After 20 min of centrifugation at 931 x g at RT, the interface was isolated and resuspended in FACS buffer. LNs (axillary and inguinal) were incubated in 400 U/ml Collagenase D (Roche Applied Science, Penzberg, Germany) and 0.1 mg/ml DNase in RPMI 1640 with 10% fetal bovine serum for 40 min at 37°C and then minced through a 40-μm cell strainer. In some experiments, LNs were heat-treated at 60°C in a hot water bath for 1 hour. Blood was collected with heparin (H3393, Sigma-Aldrich) and treated with red blood cell lysing buffer (R7757, Sigma-Aldrich). Single-cell suspensions were blocked with 2.4G2 culture supernatant (ATCC, Manassas, VA). Surface staining was performed in standard FACS buffer for 30 min at 4°C. Anti-CD8α (53–6.7), CD44 (IM7), CD3 (17A2), Thy1.2 (30-H12), Thy1.1 (OX-7), CD69 (H1.2F3), CD103 (2E7), BrdU (3D4), MHC-II (M5/114.15.2)<bold>,</bold> CD45.2 (104), and Annexin V were purchased from BioLegend. Anti-TGFßRIII (1C5H11) was purchased from Sigma-Aldrich. Soluble tetrameric B8R<sub>20–27</sub>/H2-K<sup>b</sup> complex (made by the NIH Tetramer Core Facility) was conjugated to PE-labeled streptavidin. A BD LSRFORTESSA (BD Biosciences) and FlowJo software (TreeStar, Ashland, OR) were used for analysis.</p></sec><sec id="s4-11"><title>Single-cell RNA and totalseq C-sequencing - sample preparation</title><sec id="s4-11-1"><title>Flow cytometry and HT antibody staining</title><p>Single-cell lymphocyte suspensions were isolated as described above and stained with anti-CD45-APC, anti-CD8a, anti-CD44, anti-CD103 and different TotalSeq-C Anti-Mouse Hashtags (TotalSeq-C Anti-Mouse Hashtags 1–10 BioLegend #155861–155879, in staining buffer (DMEM, 2% FCS and 10 mM HEPES)) for 20 min at 4°C in the dark. Standard spleen cell suspensions were stained under identical conditions but included anti-CD45-FITC (BioLegend 109806, clone 104) to differentiate them from other samples when pooled. Each sample was labeled with a unique hashtag, enabling the downstream assignment of individual cell (10x cell barcode) to their respective source samples (<xref ref-type="bibr" rid="bib57">Stoeckius et al., 2018</xref>).</p></sec></sec><sec id="s4-12"><title>Cell sorting</title><p>For each sample, 500–5000K DAPI<sup>-</sup> CD45<sup>+</sup> Thy1.2<sup>+</sup> CD8a<sup>+</sup> (skin samples) or DAPI<sup>-</sup> CD45<sup>+</sup> Thy1.2<sup>+</sup> CD8a<sup>+</sup> CD44<sup>+</sup> CD103<sup>+</sup> (LN samples) T cells were sorted on the FACSAria III and pooled in a single collection tube at 4C. DAPI was added just before the sort.</p></sec><sec id="s4-13"><title>ImmGenT TotalSeq-C custom mouse panel staining</title><p>The pooled single-cell suspension was stained with the ImmGenT TotalSeq-C custom mouse panel, containing 128 antibodies (BioLegend Part no. 900004815) and FcBlock (Bio X Cell #BE0307). Because 500,000 cells are required for staining, unstained splenocytes were spiked in to reach a total of 500,000 cells.</p></sec><sec id="s4-14"><title>Second sort</title><p>Cells were subsequently sorted a second time with the addition of DAPI to select for live T cells, and include 5000 total splenocyte standard cells that were sorted into a single collection tube.</p></sec><sec id="s4-15"><title>Single-cell RNA and totalseq C-sequencing - library preparation</title><sec id="s4-15-1"><title>Cell encapsulation and cDNA library</title><p>Single-cell RNA sequencing was performed using the 10x Genomics 5' v2 platform with Feature Barcoding for Cell Surface Protein and Immune Receptor Mapping, adhering to the manufacturer’s guidelines (CG000330). After cell encapsulation with the Chromium Controller, reverse transcription and PCR amplification were performed in the emulsion. From the amplified cDNA library, smaller fragments containing TotalSeq-C-derived cDNA were separated for Feature Barcode library construction, while larger fragments containing transcript-derived cDNA were preserved for TCR and Gene Expression library generation. Library sizes for both cDNA fractions were evaluated using the Agilent Bioanalyzer 2100 High Sensitivity DNA assay and quantified with a Qubit dsDNA HS Assay kit on a Qubit 4.0 Fluorometer.</p></sec><sec id="s4-15-2"><title>RNA library construction</title><p>After enzymatic fragmentation and size selection of the cDNA, the library was ligated to an Illumina R2 sequence and indexed using unique Dual Index TT set A index sequences, SI-TT-B6.</p></sec><sec id="s4-15-3"><title>TotalSeq-C library construction</title><p>Totalseq-C derived cDNA was processed into the Feature Barcode libraries following the manufacturer’s protocol. The library was indexed with a unique dual index TN set TN set A (10x part no. 3000510) index sequence SI-TN-F9.</p></sec><sec id="s4-15-4"><title>Sequencing</title><p>The three libraries were pooled based on molarity in the following proportions: 47.5% RNA, 47.5% Feature Barcode, and 5% TCR. The pooled libraries were sequenced on an Illumina NovaSeq S2 platform (100 cycles) using the 10x Genomics specifications: 26 cycles for Read 1, 10 cycles for Index 1, 10 cycles for Index 2, and 90 cycles for Read 2.</p></sec></sec><sec id="s4-16"><title>Single-cell RNA, TCR and totalseq C-sequencing - data processing</title><sec id="s4-16-1"><title>Code</title><p>Code is available on <ext-link ext-link-type="uri" xlink:href="https://github.com/dzemmour/immgen_t">https://github.com/dzemmour/immgen_t</ext-link>, copy archived at <xref ref-type="bibr" rid="bib11">Casey and Zemmour, 2025</xref>.</p></sec><sec id="s4-16-2"><title>Count matrices</title><p>Gene and TotalSeq-C antibody (surface protein panel and hashtags) counts were obtained by aligning reads to the mm10 (GRCm38) mouse genome using the M25 (GRCm38.p6) Gencode annotation and the DNA barcodes for the TotalSeq-C panel. Alignment was performed with CellRanger software (v7.1.0, 10x Genomics) using default parameters. Cells were identified and separated from droplets with high RNA and TotalSeq-C counts by determining inflection points on the total count curve, using the barcodeRanks function from the DropletUtils package.</p></sec><sec id="s4-16-3"><title>Sample demultiplexing</title><p>Sample demultiplexing was performed using hashtag counts and the HTODemux function from the Seurat package (Seurat v4.1). Doublets (droplets containing two hashtags) were excluded, and cells were assigned to the hashtag with the highest signal, provided it had at least 10 counts and was more than double the signal of the second most abundant hashtag. Hashtag count data were also visualized using t-SNE to ensure clear separation of clusters corresponding to each hashtag. All single cells from the gene count matrix were uniquely matched to a single hashtag, thereby linking them unambiguously to their original sample.</p></sec><sec id="s4-16-4"><title>Quality control (QC) and batch correction</title><p>Cells meeting any of the following criteria were excluded from the analysis: fewer than 500 RNA counts, dead cells with over 10% of counts mapping to mitochondrial genes, fewer than 500 TotalSeq-C counts, or positivity for two isotype controls (indicating non-specific TotalSeq-C antibody binding). Non-T cells were excluded based on the expression of the MNP gene signature, B cell signature, ILC gene signature, and the absence of T cell gene signature (score calculated using AddModuleScore_UCell). CITE-seq data did not meet quality control and was not used in the analysis.</p></sec><sec id="s4-16-5"><title>ImmGen T integration</title><p>The data was integrated with the rest of the ImmgenT dataset using the SCVI.TOTALVI model (v1.2.0) and the 10x lane as a batch parameter. Dimensionality reduction was performed using the pymde.preserve_neighbors() function with default parameters [<ext-link ext-link-type="uri" xlink:href="https://pymde.org/citing/index.html">https://pymde.org/citing/index.html</ext-link>]. Cell clustering was carried out using the FindClusters() function in Seurat. Manual annotation by the immgenT consortium was done using protein and RNA expression of Cd3e, Trbc1, Trbc2, Cd4, Cd8a, Cd8b1, Foxp3, Mki67, Sell, Cd44, Trgc1, Itgax, Itgam, Ms4a1, CD3, TCRB, THY1.2, CD4, CD8A, CD8B, CD62L, CD44, TCRGD, TCRVG1.1, TCRVG2, TCRVG3, CD19, CD20, ITAM.CD11B, ITAX.CD11C, KLRBC-NK1.1. Data was visualized using the Rosetta software (<ext-link ext-link-type="uri" xlink:href="https://cbdm.connect.hms.harvard.edu/ImmgenT/PublicRosetta/">https://cbdm.connect.hms.harvard.edu/ImmgenT/PublicRosetta/</ext-link>). ImmgenT integration and annotation available on <ext-link ext-link-type="uri" xlink:href="https://www.immgen.org/ImmGenT/">https://www.immgen.org/ImmGenT/</ext-link>.</p><p>The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (<xref ref-type="bibr" rid="bib19">Hao et al., 2024</xref>). The SubSeries data discussed in this paper are accessible through the GEO accession number GSE283941 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283941">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283941</ext-link>). The ImmgenT SuperSeries data are accessible through the GEO accession number GSE297097 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297097">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297097</ext-link>).</p></sec><sec id="s4-16-6"><title>Clustering and dimensionality reduction</title><p>Using Seurat v4.2. [<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/31178118/">https://pubmed.ncbi.nlm.nih.gov/31178118/</ext-link>], the variance-stabilizing transformation (VST method) was applied, and PCA was conducted on the top 2000 genes. Principal components explaining 80% of the total variance were selected for two-dimensional reduction using UMAP. Clustering was performed on these principal components using the FindClusters() function in Seurat.</p></sec><sec id="s4-16-7"><title>Differential Expression</title><p>To determine differentially expressed genes, FindMarkers() within Seurat was used. AddModuleScore() was used to visualize aggregated expression of a set of genes. Volcano plots were created using EnhancedVolcano (v1.14.0).</p></sec><sec id="s4-16-8"><title>Signature score analysis</title><p>Signature score was calculated by first generating differentially expressed genes of each cluster or condition compared to naïve T cells from the spleen control, and then calculating an average z-score for every up and down gene in a core gene signature datasets. The core gene datasets were generated by <xref ref-type="bibr" rid="bib24">Jaiswal et al., 2022</xref> by calculating the exclusive expression of genes from T-cells in the datasets GSE47045 (<xref ref-type="bibr" rid="bib33">Mackay et al., 2013</xref>), GSE10239 (<xref ref-type="bibr" rid="bib51">Sarkar et al., 2008</xref>) and GSE41867 (<xref ref-type="bibr" rid="bib14">Doering et al., 2012</xref>). Comparative programs for T<sub>RM</sub> development over time were analyzed against the transcripts taken from the top 100 differentially expressed genes of each T<sub>RM</sub> timepoint/ naïve from GSE79805 (<xref ref-type="bibr" rid="bib45">Pan et al., 2017</xref>) by adapting published scoring methods with this data set (<xref ref-type="bibr" rid="bib24">Jaiswal et al., 2022</xref>). The overall signature score was scored based on expression data that was quantified using RSEM in transcripts per million (TPM), then log-transformed as log2 (TPM+ 1). It was then centered for each gene across all cells. The centered data was averaged across sets of genes to define signature scores. We subtracted a control score from the signature score, which is defined using the same process on randomly selected gene sets. A randomized control was generated by the average enrichment of each group compared to a randomly generated gene set of an equal number of probes, as iterated (<xref ref-type="bibr" rid="bib24">Jaiswal et al., 2022</xref>).</p></sec><sec id="s4-16-9"><title>Quantification and statistical analysis</title><p>Groups were compared with Prism software (GraphPad) using two-tailed paired Student’s t-test for comparison of left and right flanks, two-tailed unpaired Student’s t-test for comparison between animals, or Dunnett’s test for comparisons of more than two groups. Sample size was determined by an a priori power analysis with an α of 0.05 and a 1-β of 0.80 based on pilot data. Data is presented as each data point and mean with the standard error of the mean (s.e.m.). <italic>P</italic>&lt;0.05 was considered significant. Studies were designed in accordance with ARRIVE guidelines. Researchers were blinded for all sample analysis. All experimental data was included in the figures, and mice were randomly assigned to groups when appropriate.</p></sec></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>serves as a consultant or is on the advisory board for Shennon Biotechnologies, Panther Life Sciences, Verrica pharmaceuticals, Genmab, 23 and me, Johnson and Johnson, Lytix Biopharma</p></fn><fn fn-type="COI-statement" id="conf3"><p>is a paid consultant for AbbVie Inc, Beiersdorf AG, Janssen Research and Development LLC, and Aditum Bio; has a sponsored research agreement with Galderma Laboratories, Lp</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Conceptualization</p></fn><fn fn-type="con" id="con13"><p>Software, Methodology</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Data curation, Software, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con16"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All mice were maintained under specific-pathogen-free conditions and all animal experiments were approved by University of Pittsburgh Institutional Animal Care and Use Committee under the Animal Welfare Assurance Number D16-00118 (A3187-01).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-107096-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All scRNA-seq is available within GEO GSE283941 and GSE297097. Code used in this paper can be found at <ext-link ext-link-type="uri" xlink:href="https://www.immgen.org/ImmGenT/">https://www.immgen.org/ImmGenT/</ext-link>, or it is cited within the text.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>ES</given-names></name><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lui</surname><given-names>A</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Magill</surname><given-names>I</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Anandasabapathy</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Zemmour</surname><given-names>D</given-names></name><name><surname>MacKay</surname><given-names>L</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Development of Fit Epidermal Resident Memory T Cells Requires Antigen Encounter in the Skin</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283941">GSE283941</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Zemmour</surname><given-names>D</given-names></name><name><surname>Goldrath</surname><given-names>A</given-names></name><name><surname>Kronenberg</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>The ImmgenT Open-Source project</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297097">GSE297097</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Daniel Bernard (Division of Endocrinology and Metabolism, McGill University, Montreal, Canada) for providing the Tgfbr3<sup>fl/fl</sup> mice. We thank the members of the Kaplan and Vignali laboratories and members throughout the departments of Dermatology and Immunology for helpful discussions. We also thank the Division of Laboratory Animal Resources of the University of Pittsburgh for excellent animal care.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Sugihara</surname><given-names>E</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Ikuta</surname><given-names>K</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name><name><surname>Amagai</surname><given-names>M</given-names></name><name><surname>Nagao</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma</article-title><source>Nature Medicine</source><volume>21</volume><fpage>1272</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1038/nm.3962</pub-id><pub-id pub-id-type="pmid">26479922</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>RS</given-names></name><name><surname>Smith</surname><given-names>CM</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>van Lint</surname><given-names>AL</given-names></name><name><surname>Wakim</surname><given-names>LM</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells</article-title><source>Science</source><volume>301</volume><fpage>1925</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1126/science.1087576</pub-id><pub-id pub-id-type="pmid">14512632</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aluwihare</surname><given-names>P</given-names></name><name><surname>Mu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Weinreb</surname><given-names>PH</given-names></name><name><surname>Horan</surname><given-names>GS</given-names></name><name><surname>Violette</surname><given-names>SM</given-names></name><name><surname>Munger</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice</article-title><source>Journal of Cell Science</source><volume>122</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1242/jcs.035246</pub-id><pub-id pub-id-type="pmid">19118215</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atsaves</surname><given-names>V</given-names></name><name><surname>Leventaki</surname><given-names>V</given-names></name><name><surname>Rassidakis</surname><given-names>GZ</given-names></name><name><surname>Claret</surname><given-names>FX</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>AP-1 transcription factors as regulators of immune responses in cancer</article-title><source>Cancers</source><volume>11</volume><elocation-id>1037</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11071037</pub-id><pub-id pub-id-type="pmid">31340499</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedoui</surname><given-names>S</given-names></name><name><surname>Whitney</surname><given-names>PG</given-names></name><name><surname>Waithman</surname><given-names>J</given-names></name><name><surname>Eidsmo</surname><given-names>L</given-names></name><name><surname>Wakim</surname><given-names>L</given-names></name><name><surname>Caminschi</surname><given-names>I</given-names></name><name><surname>Allan</surname><given-names>RS</given-names></name><name><surname>Wojtasiak</surname><given-names>M</given-names></name><name><surname>Shortman</surname><given-names>K</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells</article-title><source>Nature Immunology</source><volume>10</volume><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/ni.1724</pub-id><pub-id pub-id-type="pmid">19349986</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behr</surname><given-names>FM</given-names></name><name><surname>Parga-Vidal</surname><given-names>L</given-names></name><name><surname>Kragten</surname><given-names>NAM</given-names></name><name><surname>van Dam</surname><given-names>TJP</given-names></name><name><surname>Wesselink</surname><given-names>TH</given-names></name><name><surname>Sheridan</surname><given-names>BS</given-names></name><name><surname>Arens</surname><given-names>R</given-names></name><name><surname>van Lier</surname><given-names>RAW</given-names></name><name><surname>Stark</surname><given-names>R</given-names></name><name><surname>van Gisbergen</surname><given-names>KPJM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tissue-resident memory CD8<sup>+</sup> T cells shape local and systemic secondary T cell responses</article-title><source>Nature Immunology</source><volume>21</volume><fpage>1070</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0723-4</pub-id><pub-id pub-id-type="pmid">32661361</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Mitchell</surname><given-names>JS</given-names></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Mohammed</surname><given-names>J</given-names></name><name><surname>Wijeyesinghe</surname><given-names>S</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Burbach</surname><given-names>BJ</given-names></name><name><surname>Hickman</surname><given-names>HD</given-names></name><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Fife</surname><given-names>BT</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Intravital mucosal imaging of CD8<sup>+</sup> resident memory T cells shows tissue-autonomous recall responses that amplify secondary memory</article-title><source>Nature Immunology</source><volume>19</volume><fpage>173</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0029-3</pub-id><pub-id pub-id-type="pmid">29311694</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Wijeyesinghe</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Macchietto</surname><given-names>MG</given-names></name><name><surname>Rosato</surname><given-names>PC</given-names></name><name><surname>Pierson</surname><given-names>MJ</given-names></name><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Mitchell</surname><given-names>JS</given-names></name><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Fife</surname><given-names>BT</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>T Cells in nonlymphoid tissues give rise to lymph-node-resident memory T cells</article-title><source>Immunity</source><volume>48</volume><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.01.015</pub-id><pub-id pub-id-type="pmid">29466758</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Gray</surname><given-names>SM</given-names></name><name><surname>Nowyhed</surname><given-names>HN</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Gibson</surname><given-names>JA</given-names></name><name><surname>Abraham</surname><given-names>C</given-names></name><name><surname>Narayan</surname><given-names>D</given-names></name><name><surname>Vasquez</surname><given-names>J</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Dhodapkar</surname><given-names>KM</given-names></name><name><surname>Kaech</surname><given-names>SM</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>3905</fpage><lpage>3916</lpage><pub-id pub-id-type="doi">10.1172/JCI85329</pub-id><pub-id pub-id-type="pmid">27617863</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buquicchio</surname><given-names>FA</given-names></name><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>PK</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Evrard</surname><given-names>M</given-names></name><name><surname>Obers</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>JC</given-names></name><name><surname>Raposo</surname><given-names>CJ</given-names></name><name><surname>Belk</surname><given-names>JA</given-names></name><name><surname>Daniel</surname><given-names>B</given-names></name><name><surname>Zareie</surname><given-names>P</given-names></name><name><surname>Yost</surname><given-names>KE</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Nico</surname><given-names>KF</given-names></name><name><surname>Tierney</surname><given-names>FM</given-names></name><name><surname>Howitt</surname><given-names>MR</given-names></name><name><surname>Lareau</surname><given-names>CA</given-names></name><name><surname>Satpathy</surname><given-names>AT</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Distinct epigenomic landscapes underlie tissue-specific memory T cell differentiation</article-title><source>Immunity</source><volume>57</volume><fpage>2202</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.06.014</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>O</given-names></name><name><surname>Zemmour</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Immgen_t</data-title><version designator="swh:1:rev:ab3e15d7bc56684bf0118840e02b8e850aa6d944">swh:1:rev:ab3e15d7bc56684bf0118840e02b8e850aa6d944</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:41b96eda25961a2c7382df76ecce4629c8f44725;origin=https://github.com/dzemmour/immgen_t;visit=swh:1:snp:22cfbba4bb3822825ab96d31101c9c8310ebdd49;anchor=swh:1:rev:ab3e15d7bc56684bf0118840e02b8e850aa6d944">https://archive.softwareheritage.org/swh:1:dir:41b96eda25961a2c7382df76ecce4629c8f44725;origin=https://github.com/dzemmour/immgen_t;visit=swh:1:snp:22cfbba4bb3822825ab96d31101c9c8310ebdd49;anchor=swh:1:rev:ab3e15d7bc56684bf0118840e02b8e850aa6d944</ext-link></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Çuburu</surname><given-names>N</given-names></name><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Buck</surname><given-names>CB</given-names></name><name><surname>Kines</surname><given-names>RC</given-names></name><name><surname>Pang</surname><given-names>Y-YS</given-names></name><name><surname>Day</surname><given-names>PM</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses</article-title><source>The Journal of Clinical Investigation</source><volume>122</volume><fpage>4606</fpage><lpage>4620</lpage><pub-id pub-id-type="doi">10.1172/JCI63287</pub-id><pub-id pub-id-type="pmid">23143305</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Prier</surname><given-names>JE</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cutting Edge: tissue-resident memory T cells generated by multiple immunizations or localized deposition provide enhanced immunity</article-title><source>Journal of Immunology</source><volume>198</volume><fpage>2233</fpage><lpage>2237</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601367</pub-id><pub-id pub-id-type="pmid">28159905</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doering</surname><given-names>TA</given-names></name><name><surname>Crawford</surname><given-names>A</given-names></name><name><surname>Angelosanto</surname><given-names>JM</given-names></name><name><surname>Paley</surname><given-names>MA</given-names></name><name><surname>Ziegler</surname><given-names>CG</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory</article-title><source>Immunity</source><volume>37</volume><fpage>1130</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.08.021</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitz Patrick</surname><given-names>MEB</given-names></name><name><surname>Provine</surname><given-names>NM</given-names></name><name><surname>Garner</surname><given-names>LC</given-names></name><name><surname>Powell</surname><given-names>K</given-names></name><name><surname>Amini</surname><given-names>A</given-names></name><name><surname>Irwin</surname><given-names>SL</given-names></name><name><surname>Ferry</surname><given-names>H</given-names></name><name><surname>Ambrose</surname><given-names>T</given-names></name><name><surname>Friend</surname><given-names>P</given-names></name><name><surname>Vrakas</surname><given-names>G</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Soilleux</surname><given-names>E</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>Allan</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human intestinal tissue-resident memory T cells comprise transcriptionally and functionally distinct subsets</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108661</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108661</pub-id><pub-id pub-id-type="pmid">33472060</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>R</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Quarnstrom</surname><given-names>CF</given-names></name><name><surname>Ghoneim</surname><given-names>HE</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zebley</surname><given-names>CC</given-names></name><name><surname>Scott</surname><given-names>MC</given-names></name><name><surname>Fares-Frederickson</surname><given-names>NJ</given-names></name><name><surname>Wijeyesinghe</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Borges da Silva</surname><given-names>H</given-names></name><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Youngblood</surname><given-names>B</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Developmental plasticity allows outside-in immune responses by resident memory T cells</article-title><source>Nature Immunology</source><volume>21</volume><fpage>412</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0607-7</pub-id><pub-id pub-id-type="pmid">32066954</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazon</surname><given-names>H</given-names></name><name><surname>Barbeau</surname><given-names>B</given-names></name><name><surname>Mesnard</surname><given-names>JM</given-names></name><name><surname>Peloponese</surname><given-names>JM</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hijacking of the AP-1 signaling pathway during development of ATL</article-title><source>Frontiers in Microbiology</source><volume>8</volume><elocation-id>2686</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02686</pub-id><pub-id pub-id-type="pmid">29379481</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebhardt</surname><given-names>T</given-names></name><name><surname>Whitney</surname><given-names>PG</given-names></name><name><surname>Zaid</surname><given-names>A</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Mueller</surname><given-names>SN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Different patterns of peripheral migration by memory CD4+ and CD8+ T cells</article-title><source>Nature</source><volume>477</volume><fpage>216</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1038/nature10339</pub-id><pub-id pub-id-type="pmid">21841802</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Kowalski</surname><given-names>MH</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Molla</surname><given-names>G</given-names></name><name><surname>Madad</surname><given-names>S</given-names></name><name><surname>Fernandez-Granda</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Dictionary learning for integrative, multimodal and scalable single-cell analysis</article-title><source>Nature Biotechnology</source><volume>42</volume><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01767-y</pub-id><pub-id pub-id-type="pmid">37231261</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Heldin</surname><given-names>CH</given-names></name><name><surname>Moustakas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Signaling Receptors for TGF-β Family Members</source><publisher-name>Cold Spring Harb Perspect Biol</publisher-name><pub-id pub-id-type="doi">10.1101/cshperspect.a022053</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Zenke</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Bartholin</surname><given-names>L</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Keratinocyte-mediated activation of the cytokine TGF-β maintains skin recirculating memory CD8<sup>+</sup> T cells</article-title><source>Immunity</source><volume>50</volume><fpage>1249</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.002</pub-id><pub-id pub-id-type="pmid">30952606</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Whitley</surname><given-names>SK</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Migration and function of memory CD8+ T Cells in skin</article-title><source>Journal of Investigative Dermatology</source><volume>140</volume><fpage>748</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2019.09.014</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zenke</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chaudhri</surname><given-names>VK</given-names></name><name><surname>De La Cruz Diaz</surname><given-names>JS</given-names></name><name><surname>Zhou</surname><given-names>PY</given-names></name><name><surname>Nguyen</surname><given-names>BA-T</given-names></name><name><surname>Bartholin</surname><given-names>L</given-names></name><name><surname>Workman</surname><given-names>CJ</given-names></name><name><surname>Griggs</surname><given-names>DW</given-names></name><name><surname>Vignali</surname><given-names>DAA</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Competition for active TGFβ cytokine allows for selective retention of antigen-specific tissue- resident memory T cells in the epidermal niche</article-title><source>Immunity</source><volume>54</volume><fpage>84</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.10.022</pub-id><pub-id pub-id-type="pmid">33212014</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>A</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Dannenfelser</surname><given-names>R</given-names></name><name><surname>Melssen</surname><given-names>M</given-names></name><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>T-G</given-names></name><name><surname>Nirschl</surname><given-names>CJ</given-names></name><name><surname>Devi</surname><given-names>KSP</given-names></name><name><surname>Olson</surname><given-names>WC</given-names><suffix>Jr</suffix></name><name><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name><name><surname>Engelhard</surname><given-names>VH</given-names></name><name><surname>Garraway</surname><given-names>L</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Minkis</surname><given-names>K</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><name><surname>Troyanskaya</surname><given-names>O</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Suárez-Fariñas</surname><given-names>M</given-names></name><name><surname>Anandasabapathy</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes</article-title><source>Cancer Cell</source><volume>40</volume><fpage>524</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2022.04.005</pub-id><pub-id pub-id-type="pmid">35537413</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jennings</surname><given-names>E</given-names></name><name><surname>Elliot</surname><given-names>TAE</given-names></name><name><surname>Thawait</surname><given-names>N</given-names></name><name><surname>Kanabar</surname><given-names>S</given-names></name><name><surname>Yam-Puc</surname><given-names>JC</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Toellner</surname><given-names>KM</given-names></name><name><surname>Wraith</surname><given-names>DC</given-names></name><name><surname>Anderson</surname><given-names>G</given-names></name><name><surname>Bending</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nr4a1 and Nr4a3 reporter mice are differentially sensitive to T cell receptor signal strength and duration</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108328</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108328</pub-id><pub-id pub-id-type="pmid">33147449</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wagers</surname><given-names>AJ</given-names></name><name><surname>Fuhlbrigge</surname><given-names>RC</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity</article-title><source>Nature</source><volume>483</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nature10851</pub-id><pub-id pub-id-type="pmid">22388819</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korsunsky</surname><given-names>I</given-names></name><name><surname>Millard</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Slowikowski</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>K</given-names></name><name><surname>Baglaenko</surname><given-names>Y</given-names></name><name><surname>Brenner</surname><given-names>M</given-names></name><name><surname>Loh</surname><given-names>P-R</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fast, sensitive and accurate integration of single-cell data with Harmony</article-title><source>Nature Methods</source><volume>16</volume><fpage>1289</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0619-0</pub-id><pub-id pub-id-type="pmid">31740819</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurd</surname><given-names>NS</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Louis</surname><given-names>TL</given-names></name><name><surname>Milner</surname><given-names>JJ</given-names></name><name><surname>Omilusik</surname><given-names>KD</given-names></name><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Tsai</surname><given-names>MS</given-names></name><name><surname>Widjaja</surname><given-names>CE</given-names></name><name><surname>Kanbar</surname><given-names>JN</given-names></name><name><surname>Olvera</surname><given-names>JG</given-names></name><name><surname>Tysl</surname><given-names>T</given-names></name><name><surname>Quezada</surname><given-names>LK</given-names></name><name><surname>Boland</surname><given-names>BS</given-names></name><name><surname>Huang</surname><given-names>WJ</given-names></name><name><surname>Murre</surname><given-names>C</given-names></name><name><surname>Goldrath</surname><given-names>AW</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Early precursors and molecular determinants of tissue-resident memory CD8 <sup>+</sup> T lymphocytes revealed by single-cell RNA sequencing</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>6894</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aaz6894</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Suarez-Ramirez</surname><given-names>JE</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Redman</surname><given-names>JM</given-names></name><name><surname>Bouchard</surname><given-names>K</given-names></name><name><surname>Hadley</surname><given-names>GA</given-names></name><name><surname>Cauley</surname><given-names>LS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Environmental and antigen receptor-derived signals support sustained surveillance of the lungs by pathogen-specific cytotoxic T lymphocytes</article-title><source>Journal of Virology</source><volume>85</volume><fpage>4085</fpage><lpage>4094</lpage><pub-id pub-id-type="doi">10.1128/JVI.02493-10</pub-id><pub-id pub-id-type="pmid">21345961</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Fortin</surname><given-names>J</given-names></name><name><surname>Ongaro</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Boehm</surname><given-names>U</given-names></name><name><surname>Schneyer</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>DJ</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Betaglycan (TGFBR3) functions as an inhibin A, but not inhibin B, coreceptor in pituitary gonadotrope cells in mice</article-title><source>Endocrinology</source><volume>159</volume><fpage>4077</fpage><lpage>4091</lpage><pub-id pub-id-type="doi">10.1210/en.2018-00770</pub-id><pub-id pub-id-type="pmid">30364975</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Fuhlbrigge</surname><given-names>RC</given-names></name><name><surname>Karibian</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Dynamic programming of CD8+ T cell trafficking after live viral immunization</article-title><source>Immunity</source><volume>25</volume><fpage>511</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.06.019</pub-id><pub-id pub-id-type="pmid">16973385</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>LK</given-names></name><name><surname>Stock</surname><given-names>AT</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Kent</surname><given-names>SJ</given-names></name><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation</article-title><source>PNAS</source><volume>109</volume><fpage>7037</fpage><lpage>7042</lpage><pub-id pub-id-type="doi">10.1073/pnas.1202288109</pub-id><pub-id pub-id-type="pmid">22509047</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>LK</given-names></name><name><surname>Rahimpour</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name><name><surname>Collins</surname><given-names>N</given-names></name><name><surname>Stock</surname><given-names>AT</given-names></name><name><surname>Hafon</surname><given-names>M-L</given-names></name><name><surname>Vega-Ramos</surname><given-names>J</given-names></name><name><surname>Lauzurica</surname><given-names>P</given-names></name><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Stefanovic</surname><given-names>T</given-names></name><name><surname>Tscharke</surname><given-names>DC</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Inouye</surname><given-names>M</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin</article-title><source>Nature Immunology</source><volume>14</volume><fpage>1294</fpage><lpage>1301</lpage><pub-id pub-id-type="doi">10.1038/ni.2744</pub-id><pub-id pub-id-type="pmid">24162776</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>LK</given-names></name><name><surname>Wynne-Jones</surname><given-names>E</given-names></name><name><surname>Freestone</surname><given-names>D</given-names></name><name><surname>Pellicci</surname><given-names>DG</given-names></name><name><surname>Mielke</surname><given-names>LA</given-names></name><name><surname>Newman</surname><given-names>DM</given-names></name><name><surname>Braun</surname><given-names>A</given-names></name><name><surname>Masson</surname><given-names>F</given-names></name><name><surname>Kallies</surname><given-names>A</given-names></name><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>T-box transcription factors combine with the cytokines TGF-β and IL-15 to control tissue-resident memory T cell fate</article-title><source>Immunity</source><volume>43</volume><fpage>1101</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.11.008</pub-id><pub-id pub-id-type="pmid">26682984</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>V</given-names></name><name><surname>Bromley</surname><given-names>SK</given-names></name><name><surname>Äijö</surname><given-names>T</given-names></name><name><surname>Mora-Buch</surname><given-names>R</given-names></name><name><surname>Carrizosa</surname><given-names>E</given-names></name><name><surname>Warner</surname><given-names>RD</given-names></name><name><surname>Hamze</surname><given-names>M</given-names></name><name><surname>Sen</surname><given-names>DR</given-names></name><name><surname>Chasse</surname><given-names>AY</given-names></name><name><surname>Lorant</surname><given-names>A</given-names></name><name><surname>Griffith</surname><given-names>JW</given-names></name><name><surname>Rahimi</surname><given-names>RA</given-names></name><name><surname>McEntee</surname><given-names>CP</given-names></name><name><surname>Jeffrey</surname><given-names>KL</given-names></name><name><surname>Marangoni</surname><given-names>F</given-names></name><name><surname>Travis</surname><given-names>MA</given-names></name><name><surname>Lacy-Hulbert</surname><given-names>A</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Migratory DCs activate TGF-β to precondition naïve CD8<sup>+</sup> T cells for tissue-resident memory fate</article-title><source>Science</source><volume>366</volume><elocation-id>eaav5728</elocation-id><pub-id pub-id-type="doi">10.1126/science.aav5728</pub-id><pub-id pub-id-type="pmid">31601741</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Usherwood</surname><given-names>EJ</given-names></name><name><surname>Cauley</surname><given-names>LS</given-names></name><name><surname>Olson</surname><given-names>S</given-names></name><name><surname>Marzo</surname><given-names>AL</given-names></name><name><surname>Ward</surname><given-names>RL</given-names></name><name><surname>Woodland</surname><given-names>DL</given-names></name><name><surname>Lefrançois</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin</article-title><source>Journal of Immunology</source><volume>172</volume><fpage>4875</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.8.4875</pub-id><pub-id pub-id-type="pmid">15067066</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMaster</surname><given-names>SR</given-names></name><name><surname>Wein</surname><given-names>AN</given-names></name><name><surname>Dunbar</surname><given-names>PR</given-names></name><name><surname>Hayward</surname><given-names>SL</given-names></name><name><surname>Cartwright</surname><given-names>EK</given-names></name><name><surname>Denning</surname><given-names>TL</given-names></name><name><surname>Kohlmeier</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pulmonary antigen encounter regulates the establishment of tissue-resident CD8 memory T cells in the lung airways and parenchyma</article-title><source>Mucosal Immunology</source><volume>11</volume><fpage>1071</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0003-x</pub-id><pub-id pub-id-type="pmid">29453412</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milner</surname><given-names>JJ</given-names></name><name><surname>Toma</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Kurd</surname><given-names>NS</given-names></name><name><surname>Nguyen</surname><given-names>QP</given-names></name><name><surname>McDonald</surname><given-names>B</given-names></name><name><surname>Quezada</surname><given-names>L</given-names></name><name><surname>Widjaja</surname><given-names>CE</given-names></name><name><surname>Witherden</surname><given-names>DA</given-names></name><name><surname>Crowl</surname><given-names>JT</given-names></name><name><surname>Shaw</surname><given-names>LA</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>Omilusik</surname><given-names>KD</given-names></name><name><surname>Goldrath</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Heterogenous populations of tissue-resident CD8<sup>+</sup> T cells are generated in response to infection and malignancy</article-title><source>Immunity</source><volume>52</volume><fpage>808</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.007</pub-id><pub-id pub-id-type="pmid">32433949</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>TGF-beta receptors and signal transduction</article-title><source>International Journal of Hematology</source><volume>65</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/s0925-5710(96)00542-7</pub-id><pub-id pub-id-type="pmid">9071813</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>J</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Bobr</surname><given-names>A</given-names></name><name><surname>Astry</surname><given-names>B</given-names></name><name><surname>Chicoine</surname><given-names>B</given-names></name><name><surname>Kashem</surname><given-names>SW</given-names></name><name><surname>Welty</surname><given-names>NE</given-names></name><name><surname>Igyártó</surname><given-names>BZ</given-names></name><name><surname>Wijeyesinghe</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>EA</given-names></name><name><surname>Matte</surname><given-names>C</given-names></name><name><surname>Bartholin</surname><given-names>L</given-names></name><name><surname>Kaplan</surname><given-names>A</given-names></name><name><surname>Sheppard</surname><given-names>D</given-names></name><name><surname>Bridges</surname><given-names>AG</given-names></name><name><surname>Shlomchik</surname><given-names>WD</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name><name><surname>Kaplan</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stromal cells control the epithelial residence of DCs and memory T cells by regulated activation of TGF-β</article-title><source>Nature Immunology</source><volume>17</volume><fpage>414</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/ni.3396</pub-id><pub-id pub-id-type="pmid">26901152</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moutaftsi</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>B</given-names></name><name><surname>Pasquetto</surname><given-names>V</given-names></name><name><surname>Tscharke</surname><given-names>DC</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><name><surname>Bui</surname><given-names>H-H</given-names></name><name><surname>Grey</surname><given-names>H</given-names></name><name><surname>Sette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus</article-title><source>Nature Biotechnology</source><volume>24</volume><fpage>817</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1038/nbt1215</pub-id><pub-id pub-id-type="pmid">16767078</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oguejiofor</surname><given-names>K</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Slater</surname><given-names>C</given-names></name><name><surname>Betts</surname><given-names>G</given-names></name><name><surname>Hall</surname><given-names>G</given-names></name><name><surname>Slevin</surname><given-names>N</given-names></name><name><surname>Dovedi</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>PL</given-names></name><name><surname>West</surname><given-names>CML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma</article-title><source>British Journal of Cancer</source><volume>113</volume><fpage>886</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.277</pub-id><pub-id pub-id-type="pmid">26313665</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega-Francisco</surname><given-names>S</given-names></name><name><surname>de la Fuente-Granada</surname><given-names>M</given-names></name><name><surname>Alvarez Salazar</surname><given-names>EK</given-names></name><name><surname>Bolaños-Castro</surname><given-names>LA</given-names></name><name><surname>Fonseca-Camarillo</surname><given-names>G</given-names></name><name><surname>Olguin-Alor</surname><given-names>R</given-names></name><name><surname>Alemán-Muench</surname><given-names>GR</given-names></name><name><surname>López-Casillas</surname><given-names>F</given-names></name><name><surname>Raman</surname><given-names>C</given-names></name><name><surname>García-Zepeda</surname><given-names>EA</given-names></name><name><surname>Soldevila</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TβRIII is induced by TCR signaling and downregulated in FoxP3<sup>+</sup> regulatory T cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>494</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.10.081</pub-id><pub-id pub-id-type="pmid">29050936</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>DM</given-names></name><name><surname>Keyse</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases</article-title><source>Oncogene</source><volume>26</volume><fpage>3203</fpage><lpage>3213</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210412</pub-id><pub-id pub-id-type="pmid">17496916</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>CO</given-names></name><name><surname>Lofftus</surname><given-names>SY</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><name><surname>O’Malley</surname><given-names>JT</given-names></name><name><surname>Gehad</surname><given-names>A</given-names></name><name><surname>Teague</surname><given-names>JE</given-names></name><name><surname>Divito</surname><given-names>SJ</given-names></name><name><surname>Fuhlbrigge</surname><given-names>R</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Krueger</surname><given-names>JG</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Clark</surname><given-names>RA</given-names></name><name><surname>Kupper</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism</article-title><source>Nature</source><volume>543</volume><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1038/nature21379</pub-id><pub-id pub-id-type="pmid">28219080</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papavassiliou</surname><given-names>AG</given-names></name><name><surname>Musti</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The multifaceted output of c-Jun biological activity: focus at the junction of CD8 T cell activation and exhaustion</article-title><source>Cells</source><volume>9</volume><elocation-id>9112470</elocation-id><pub-id pub-id-type="doi">10.3390/cells9112470</pub-id><pub-id pub-id-type="pmid">33202877</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SL</given-names></name><name><surname>Zaid</surname><given-names>A</given-names></name><name><surname>Hor</surname><given-names>JL</given-names></name><name><surname>Christo</surname><given-names>SN</given-names></name><name><surname>Prier</surname><given-names>JE</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Alexandre</surname><given-names>YO</given-names></name><name><surname>Gregory</surname><given-names>JL</given-names></name><name><surname>Russell</surname><given-names>TA</given-names></name><name><surname>Gebhardt</surname><given-names>T</given-names></name><name><surname>Carbone</surname><given-names>FR</given-names></name><name><surname>Tscharke</surname><given-names>DC</given-names></name><name><surname>Heath</surname><given-names>WR</given-names></name><name><surname>Mueller</surname><given-names>SN</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Local proliferation maintains a stable pool of tissue-resident memory T cells after antiviral recall responses</article-title><source>Nature Immunology</source><volume>19</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0027-5</pub-id><pub-id pub-id-type="pmid">29311695</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Phasouk</surname><given-names>K</given-names></name><name><surname>Sodroski</surname><given-names>CN</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Hwangbo</surname><given-names>Y</given-names></name><name><surname>Layton</surname><given-names>ED</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Klock</surname><given-names>A</given-names></name><name><surname>Diem</surname><given-names>K</given-names></name><name><surname>Magaret</surname><given-names>AS</given-names></name><name><surname>Jing</surname><given-names>L</given-names></name><name><surname>Laing</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>ML</given-names></name><name><surname>Mertens</surname><given-names>M</given-names></name><name><surname>Johnston</surname><given-names>C</given-names></name><name><surname>Jerome</surname><given-names>KR</given-names></name><name><surname>Koelle</surname><given-names>DM</given-names></name><name><surname>Wald</surname><given-names>A</given-names></name><name><surname>Knipe</surname><given-names>DM</given-names></name><name><surname>Corey</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Tissue-resident-memory CD8<sup>+</sup> T cells bridge innate immune responses in neighboring epithelial cells to control human genital herpes</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>735643</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.735643</pub-id><pub-id pub-id-type="pmid">34552595</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynoso</surname><given-names>GV</given-names></name><name><surname>Weisberg</surname><given-names>AS</given-names></name><name><surname>Shannon</surname><given-names>JP</given-names></name><name><surname>McManus</surname><given-names>DT</given-names></name><name><surname>Shores</surname><given-names>L</given-names></name><name><surname>Americo</surname><given-names>JL</given-names></name><name><surname>Stan</surname><given-names>RV</given-names></name><name><surname>Yewdell</surname><given-names>JW</given-names></name><name><surname>Hickman</surname><given-names>HD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lymph node conduits transport virions for rapid T cell activation</article-title><source>Nature Immunology</source><volume>20</volume><fpage>602</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0342-0</pub-id><pub-id pub-id-type="pmid">30886418</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richmond</surname><given-names>JM</given-names></name><name><surname>Strassner</surname><given-names>JP</given-names></name><name><surname>Zapata</surname><given-names>L</given-names><suffix>Jr</suffix></name><name><surname>Garg</surname><given-names>M</given-names></name><name><surname>Riding</surname><given-names>RL</given-names></name><name><surname>Refat</surname><given-names>MA</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Azzolino</surname><given-names>V</given-names></name><name><surname>Tovar-Garza</surname><given-names>A</given-names></name><name><surname>Tsurushita</surname><given-names>N</given-names></name><name><surname>Pandya</surname><given-names>AG</given-names></name><name><surname>Tso</surname><given-names>JY</given-names></name><name><surname>Harris</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo</article-title><source>Science Translational Medicine</source><volume>10</volume><elocation-id>eaam7710</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aam7710</pub-id><pub-id pub-id-type="pmid">30021889</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Kalia</surname><given-names>V</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name><name><surname>Konieczny</surname><given-names>BT</given-names></name><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates</article-title><source>The Journal of Experimental Medicine</source><volume>205</volume><fpage>625</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1084/jem.20071641</pub-id><pub-id pub-id-type="pmid">18316415</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Tissue-resident memory T cells</article-title><source>Immunity</source><volume>41</volume><fpage>886</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.007</pub-id><pub-id pub-id-type="pmid">25526304</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnoegl</surname><given-names>D</given-names></name><name><surname>Hiesinger</surname><given-names>A</given-names></name><name><surname>Huntington</surname><given-names>ND</given-names></name><name><surname>Gotthardt</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity</article-title><source>Current Opinion in Immunology</source><volume>85</volume><elocation-id>102397</elocation-id><pub-id pub-id-type="doi">10.1016/j.coi.2023.102397</pub-id><pub-id pub-id-type="pmid">37931499</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schunkert</surname><given-names>EM</given-names></name><name><surname>Shah</surname><given-names>PN</given-names></name><name><surname>Divito</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Skin resident memory T cells may play critical role in delayed-type drug hypersensitivity reactions</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>654190</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.654190</pub-id><pub-id pub-id-type="pmid">34497600</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaulian</surname><given-names>E</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>AP-1 as a regulator of cell life and death</article-title><source>Nature Cell Biology</source><volume>4</volume><fpage>E131</fpage><lpage>E136</lpage><pub-id pub-id-type="doi">10.1038/ncb0502-e131</pub-id><pub-id pub-id-type="pmid">11988758</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinert</surname><given-names>EM</given-names></name><name><surname>Schenkel</surname><given-names>JM</given-names></name><name><surname>Fraser</surname><given-names>KA</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Manlove</surname><given-names>LS</given-names></name><name><surname>Igyártó</surname><given-names>BZ</given-names></name><name><surname>Southern</surname><given-names>PJ</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantifying memory CD8 T cells reveals regionalization of immunosurveillance</article-title><source>Cell</source><volume>161</volume><fpage>737</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.031</pub-id><pub-id pub-id-type="pmid">25957682</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Houck-Loomis</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Yeung</surname><given-names>BZ</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>224</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-018-1603-1</pub-id><pub-id pub-id-type="pmid">30567574</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strobl</surname><given-names>J</given-names></name><name><surname>Pandey</surname><given-names>RV</given-names></name><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Bayer</surname><given-names>N</given-names></name><name><surname>Kleissl</surname><given-names>L</given-names></name><name><surname>Reininger</surname><given-names>B</given-names></name><name><surname>Vieyra-Garcia</surname><given-names>P</given-names></name><name><surname>Wolf</surname><given-names>P</given-names></name><name><surname>Jentus</surname><given-names>MM</given-names></name><name><surname>Mitterbauer</surname><given-names>M</given-names></name><name><surname>Wohlfarth</surname><given-names>P</given-names></name><name><surname>Rabitsch</surname><given-names>W</given-names></name><name><surname>Stingl</surname><given-names>G</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Stary</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eabb7028</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abb7028</pub-id><pub-id pub-id-type="pmid">33208504</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong Rodrigues</surname><given-names>K</given-names></name><name><surname>Oliveira-Ribeiro</surname><given-names>C</given-names></name><name><surname>de Abreu Fiuza Gomes</surname><given-names>S</given-names></name><name><surname>Knobler</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cutaneous graft-versus-host disease: diagnosis and treatment</article-title><source>American Journal of Clinical Dermatology</source><volume>19</volume><fpage>33</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s40257-017-0306-9</pub-id><pub-id pub-id-type="pmid">28656563</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Yue</surname><given-names>TT</given-names></name><name><surname>Yang</surname><given-names>CL</given-names></name><name><surname>Wang</surname><given-names>FX</given-names></name><name><surname>Luo</surname><given-names>JH</given-names></name><name><surname>Rong</surname><given-names>SJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The MAPK dual specific phosphatase (DUSP) proteins: A versatile wrestler in T cell functionality</article-title><source>International Immunopharmacology</source><volume>98</volume><elocation-id>107906</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2021.107906</pub-id><pub-id pub-id-type="pmid">34198238</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>PA</given-names></name><name><surname>Miron</surname><given-names>M</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Location, location, location: Tissue resident memory T cells in mice and humans</article-title><source>Science Immunology</source><volume>4</volume><elocation-id>9673</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aas9673</pub-id><pub-id pub-id-type="pmid">30952804</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Boorn</surname><given-names>JG</given-names></name><name><surname>Konijnenberg</surname><given-names>D</given-names></name><name><surname>Dellemijn</surname><given-names>TAM</given-names></name><name><surname>van der Veen</surname><given-names>JPW</given-names></name><name><surname>Bos</surname><given-names>JD</given-names></name><name><surname>Melief</surname><given-names>CJM</given-names></name><name><surname>Vyth-Dreese</surname><given-names>FA</given-names></name><name><surname>Luiten</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients</article-title><source>The Journal of Investigative Dermatology</source><volume>129</volume><fpage>2220</fpage><lpage>2232</lpage><pub-id pub-id-type="doi">10.1038/jid.2009.32</pub-id><pub-id pub-id-type="pmid">19242513</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virassamy</surname><given-names>B</given-names></name><name><surname>Caramia</surname><given-names>F</given-names></name><name><surname>Savas</surname><given-names>P</given-names></name><name><surname>Sant</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Christo</surname><given-names>SN</given-names></name><name><surname>Byrne</surname><given-names>A</given-names></name><name><surname>Clarke</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Teo</surname><given-names>ZL</given-names></name><name><surname>von Scheidt</surname><given-names>B</given-names></name><name><surname>Freestone</surname><given-names>D</given-names></name><name><surname>Gandolfo</surname><given-names>LC</given-names></name><name><surname>Weber</surname><given-names>K</given-names></name><name><surname>Teply-Szymanski</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Luen</surname><given-names>SJ</given-names></name><name><surname>Denkert</surname><given-names>C</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Lucas</surname><given-names>O</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name><name><surname>Darcy</surname><given-names>PK</given-names></name><name><surname>Neeson</surname><given-names>PJ</given-names></name><name><surname>Mackay</surname><given-names>LK</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Intratumoral CD8<sup>+</sup> T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer</article-title><source>Cancer Cell</source><volume>41</volume><fpage>585</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.01.004</pub-id><pub-id pub-id-type="pmid">36827978</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijeyesinghe</surname><given-names>S</given-names></name><name><surname>Beura</surname><given-names>LK</given-names></name><name><surname>Pierson</surname><given-names>MJ</given-names></name><name><surname>Stolley</surname><given-names>JM</given-names></name><name><surname>Adam</surname><given-names>OA</given-names></name><name><surname>Ruscher</surname><given-names>R</given-names></name><name><surname>Steinert</surname><given-names>EM</given-names></name><name><surname>Rosato</surname><given-names>PC</given-names></name><name><surname>Vezys</surname><given-names>V</given-names></name><name><surname>Masopust</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Expansible residence decentralizes immune homeostasis</article-title><source>Nature</source><volume>592</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03351-3</pub-id><pub-id pub-id-type="pmid">33731934</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worthington</surname><given-names>JJ</given-names></name><name><surname>Klementowicz</surname><given-names>JE</given-names></name><name><surname>Travis</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TGFβ: a sleeping giant awoken by integrins</article-title><source>Trends in Biochemical Sciences</source><volume>36</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2010.08.002</pub-id><pub-id pub-id-type="pmid">20870411</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Mu</surname><given-names>Z</given-names></name><name><surname>Dabovic</surname><given-names>B</given-names></name><name><surname>Jurukovski</surname><given-names>V</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Sung</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Munger</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice</article-title><source>The Journal of Cell Biology</source><volume>176</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1083/jcb.200611044</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehn</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Bevan</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Complete but curtailed T-cell response to very low-affinity antigen</article-title><source>Nature</source><volume>458</volume><fpage>211</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1038/nature07657</pub-id><pub-id pub-id-type="pmid">19182777</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zemmour</surname><given-names>D</given-names></name><name><surname>Goldrath</surname><given-names>A</given-names></name><name><surname>Kronenberg</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The immgen consortium openSource T cell project</article-title><source>Nature Immunology</source><volume>23</volume><fpage>643</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1038/s41590-022-01197-z</pub-id><pub-id pub-id-type="pmid">35469020</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The roles of T cells in psoriasis</article-title><source>Frontiers in Immunology</source><volume>14</volume><elocation-id>1081256</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1081256</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagent type (species) or resource</th><th align="left" valign="top">Designation</th><th align="left" valign="top">Source or reference</th><th align="left" valign="top">Identifiers</th><th align="left" valign="top">Additional information</th></tr></thead><tbody><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Brilliant Violet 605 anti-mouse CD8a (Rat monoclonal, 53–6.7)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 100744, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2562609">AB_2562609</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Alexa Fluor 647 anti-mouse CD90.1 (mouse monoclonal, OX-7)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 202508, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_492884">AB_492884</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Alexa Fluor 647 anti-human CD271 (NGFR) (mouse monoclonal, ME20.4)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 345114, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2572059">AB_2572059</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-mouse Thy1.1 (mouse monoclonal, HIS51)</td><td align="left" valign="top">Thermofisher</td><td align="left" valign="top">Cat# 14-0900-85, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_467374">AB_467374</ext-link></td><td align="char" char="." valign="top">1:100</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">PerCP/Cyanine5.5 anti-mouse/human CD44 (rat monoclonal, IM7)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 103032, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2076204">AB_2076204</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Alexa Fluor 700 anti-mouse CD3 (rat monoclonal, 17A2)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 100216, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_493697">AB_493697</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">FITC anti-mouse CD90.2 (rat monoclonal, 30-H12)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 105305, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_313176">AB_313176</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">BUV737 anti-mouse CD69 (Armenian hamster monoclonal, H1.2F3)</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">Cat# 612793, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2870120">AB_2870120</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Brilliant Violet 510 anti-mouse CD103 (Armenian hamster monoclonal, 2E7)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 121423, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2562713">AB_2562713</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">FITC anti-BrdU (mouse monoclonal, 3D4)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 364103, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2564480">AB_2564480</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">APC anti-mouse CD45.2 (mouse monoclonal, 104)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 109841, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2563485">AB_2563485</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">FITC anti-mouse CD45.2 (mouse monoclonal, 104)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 109805, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_313442">AB_313442</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Alexa Fluor 700 anti-mouse I-A/I-E (rat monoclonal, M5/144.15.2)</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 107621, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_493726">AB_493726</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Antibody</td><td align="left" valign="top">Anti-TGFßRIII (1C5H11)</td><td align="left" valign="top">Novus</td><td align="left" valign="top">Cat# NBP2-37418, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_3296314">AB_3296314</ext-link></td><td align="char" char="." valign="top">1:200</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">DNFB</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">D1529</td><td align="left" valign="top">1-fluoro-2,4-dinitrobenzene</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Olive oil</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">O1514</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">DMSO</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">D2650</td><td align="left" valign="top">Dimethyl sulfoxide</td></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">CWHM12</td><td align="left" valign="top">Indalo therapeutics</td><td align="left" valign="top">N/A</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Tamoxifen</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">T5648</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Corn oil</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">C8267</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">BrdU</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">B5002</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">ProLong Gold Antifade Mount with DNA stains DAPI</td><td align="left" valign="top">Thermofisher</td><td align="left" valign="top">P36931</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">FTY720</td><td align="left" valign="top">Fisher/Cayan Chemical</td><td align="left" valign="top">Cat# 10006292</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Collagenase XI</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# 9001-12-1</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">DNase</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# 04536282001</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">4-(2-hydroxyethyl)–1-piperazineethanesulfonic acid</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# 7365-45-9</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Percoll</td><td align="left" valign="top">VWR</td><td align="left" valign="top">Cat# 89428–524</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Collagenase D</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# 11088866001</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Heparin</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# H3393</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">Red blood cell lysing buffer</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# R7757</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Chemical compound, drug</td><td align="left" valign="top">2.4G2 culture supernatant</td><td align="left" valign="top">ATCC</td><td align="left" valign="top">HB-197</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">MojoSort Mouse CD8 T Cell Isolation Kit</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">48007</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">Chromium Next GEM Single Cell 5’ Reagent Kits V2</td><td align="char" char="." valign="top">10x Genomics</td><td align="left" valign="top">Cat# CG000330</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Commercial assay or kit</td><td align="left" valign="top">dual index TN set TN set A</td><td align="char" char="." valign="top">10x Genomics</td><td align="left" valign="top">part no. 3000510</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top">Thy1.1</td><td align="left" valign="top">The Jackson Laboratory</td><td align="left" valign="top">Jax stock #005443, CBy.PL(B6)-Thy1a/ScrJ</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top">OT-I</td><td align="left" valign="top">The Jackson Laboratory</td><td align="left" valign="top">Jax stock #003831, C57BL/6-Tg(TcraTcrb)1100Mjb/J</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top"><italic>Rag1</italic><sup>-/-</sup></td><td align="left" valign="top">The Jackson Laboratory</td><td align="left" valign="top">Jax stock #002216, Rag1-/-: B6.129S7-Rag1tm1Mom/J</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top">E8I-<italic>cre</italic>ER<sup>T2</sup></td><td align="left" valign="top">Dario A.A. Vignali (University of Pittsburgh); <xref ref-type="bibr" rid="bib21">Hirai et al., 2019</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top">ROSA26.LSL.hNGFR</td><td align="left" valign="top">Dario A.A. Vignali (University of Pittsburgh); <xref ref-type="bibr" rid="bib21">Hirai et al., 2019</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="top"><italic>Tgfbr3</italic><sup>fl/fl</sup></td><td align="left" valign="top">Herbert Y Lin (Program in Membrane Biology/Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts); <xref ref-type="bibr" rid="bib30">Li et al., 2018</xref></td><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">BZX800 fluorescent microscope</td><td align="left" valign="top">Keyence</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_023617">SCR_023617</ext-link></td><td align="left" valign="top">Microscope used for I.F.</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">GentleMACS Dissociator</td><td align="left" valign="top">Miltenyi Biotec</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_020272">SCR_020272</ext-link></td><td align="left" valign="top">See ‘Flow cytometry’ in ‘Materials and methods’ section</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">PE Annexin V</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 640907</td><td align="left" valign="top">Fluorescent stain for cells undergoing apoptosis</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">Soluble tetrameric B8R<sub>20–27</sub>/H2-K<sup>b</sup> complex</td><td align="left" valign="top">NIH Tetramer Core Facility</td><td align="left" valign="top"/><td align="left" valign="top">For identifying CD8+T cells that respond to B8R<sub>20–27</sub> peptide</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">TotalSeq-C Anti-Mouse Hashtags 1–10</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat #155861–155879</td><td align="left" valign="top">Sample identifiers to allow pooling in scRNAseq</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">FcBlock</td><td align="left" valign="top">Bio X Cell</td><td align="left" valign="top">Cat #BE0307</td><td align="left" valign="top">To reduce false positives in flow cytometry</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">NovaSeq S2 platform</td><td align="left" valign="top">Illumina</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_024569">SCR_024569</ext-link></td><td align="left" valign="top">Used for scRNA sequencing</td></tr><tr><td align="left" valign="top">Other</td><td align="left" valign="top">ImmGenT TotalSeq-C custom mouse panel</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Part no. 900004815</td><td align="left" valign="top">Custom hashtags for scRNA-seq sample identification</td></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">OVA, N4, SIINFEKL</td><td align="left" valign="top">Genscript/Fisher</td><td align="left" valign="top">gene synthesis RP10161</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Peptide, recombinant protein</td><td align="left" valign="top">Y3, SIYNFEKL</td><td align="left" valign="top">Genscript/Fisher gene synthesis RP10161</td><td align="left" valign="top">gene synthesis RP10161</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">BZ-H4A Advanced Analysis Software</td><td align="left" valign="top">Keyence</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_017375">SCR_017375</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Adobe Photoshop (v6)</td><td align="left" valign="top">Adobe</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_014199">SCR_014199</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">10 x Genomics 5' v2 platform with Feature Barcoding for Cell Surface Protein and Immune Receptor Mapping</td><td align="char" char="." valign="top">10x Genomics</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_019326">SCR_019326</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">ImmgenT single-cell RNA sequencing and processing</td><td align="left" valign="top">ImmgenT</td><td align="left" valign="top"><xref ref-type="bibr" rid="bib11">Casey and Zemmour, 2025</xref></td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.immgen.org/ImmGenT/">https://www.immgen.org/ImmGenT/</ext-link></td></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">CellRanger</td><td align="char" char="." valign="top">10x Genomics</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_023221">SCR_023221</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Seurat v4.1</td><td align="left" valign="top">Satija lab and collaborators</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_007322">SCR_007322</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">Prism v10</td><td align="left" valign="top">GraphPad</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Software, algorithm</td><td align="left" valign="top">FlowJo v10</td><td align="left" valign="top">FlowJo</td><td align="left" valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Strain, strain background (Vaccinia virus)</td><td align="left" valign="top">VV</td><td align="left" valign="top">Dr. J. Yewdell, National Institute of Allergy and Infectious Diseases</td><td align="left" valign="top">Vaccinia virus-Western Reserve strain</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Strain, strain background (Vaccinia virus)</td><td align="left" valign="top">VV-OVA</td><td align="left" valign="top">Dr. J. Yewdell, National Institute of Allergy and Infectious Diseases</td><td align="left" valign="top">Vaccinia virus-Western Reserve strain expressing OVA<sub>257-264</sub></td><td align="left" valign="top"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.107096.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Oxford</institution><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This manuscript advances the prior finding that antigen recognition in the skill helps establish skin resident memory in CD8 T cells by elucidating the role of TGFBRIII in regulating CD8+ TRM skin persistence upon topical antigen exposure. Key novelty of the your work lies in generation and use of the CD8+ T cell-specific TGFBRIII knockout model, which allows them to demonstrate the role of TGFBRIII in fine tuning the degree of CD8+ T cell skin persistence and that TGFBRIII expression is promoted by CD8+ TRM encountering their cognate antigen upon initial skin entry. This is an <bold>important</bold> finding and is supported by <bold>convincing</bold> evidence. There are concerns about the use of FTY720 and the need to establish active TGFbeta limiting conditions to further test this working model.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.107096.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>Weiss et. al. seek to delineate the mechanisms by which antigen-specific CD8+ T cells outcompete bystanders in the epidermis when active TGF-b is limiting, resulting in selective retention of these cells and more complete differentiation into the TRM phenotype.</p><p>Strengths:</p><p>They begin by demonstrating that at tissue sites where cognate antigen was expressed, CD8+ T cells adopt a more mature TRM transcriptome than cells at tissue sites where cognate antigen was never expressed. By integrating their scRNA-Seq data on TRM with the much more comprehensive ImmGenT atlas, the authors provide a very useful resource for future studies in the field. Furthermore, they conclusively show that these &quot;local antigen-experienced&quot; TRM have increased proliferative capacity and that TCR avidity during TRM formation positively correlates with their future fitness. Finally, using an elegant experimental strategy, they establish that TCR signaling in CD8+ T cells in the epidermis induces TGFBRIII expression, which likely contributes to endowing them with a competitive advantage over antigen-inexperienced TRM.</p><p>Weaknesses:</p><p>The main weakness in this paper lies in the authors' reliance on a single experimental model to derive conclusions on the role of local-antigen during the acute phase of the response by comparing T cells in model antigen-vaccinia virus (VV-OVA) exposed skin to T cells in contralateral skin exposed to DNFB 5 days after the VV-OVA exposure. In this setting, antigen-independent factors may contribute to the difference in CD8+ T cell number and phenotype at the two sites. For example, it was recently shown that very early memory precursors (formed 2 days after exposure) are more efficient at seeding the epithelial TRM compartment than those recruited to skin at later times (Silva et al, Sci Immunol, 2023). DNFB-treated skin may therefore recruit precursors with reduced TRM potential. In addition, TRM-skewed circulating memory precursors have been identified (Kok et al, JEM, 2020), and perhaps VV-OVA exposed skin more readily recruits this subset compared to DNFB-exposed skin. Therefore, when the DNFB challenge is performed 5 days after vaccinia virus, the DNFB site may already be at a disadvantage in the recruitment of CD8+ T cells that can efficiently form TRM. In addition, CD8+ T cell-extrinsic mechanisms may be at play, such as differences in myeloid cell recruitment and differentiation or local cytokine and chemokine levels in VV-infected and DNFB-treated skin that could account for differences seen in TRM phenotype and function between these two sites. Although the authors do show that providing exogenous peptide antigen at the DNFB-site rescues their phenotype in relation to the VV-OVA site, the potential antigen-independent factors distinguishing these two sites remain unaddressed. In addition, there is a possibility that peptide treatment of DNFB-treated skin initiates a second phase of priming of new circulatory effectors in the local-draining lymph nodes that are then recruited to form TRM at the DFNB-site, and that the effect does not solely rely on TRM precursors at the DNFB-treated skin site at the time of peptide treatment. These concerns are somewhat alleviated by the fact that in a prior publication (PMID: 33212014), the group has already established a role for local antigen encounter in skin in a setting where they compared contralateral ears infected with VV-OVA and VV expressing an irrelevant antigen.</p><p>Secondly, although the authors conclusively demonstrate that TGFBRIII is induced by TCR signals and required for conferring increased fitness to local-antigen experienced CD8+ TRM compared to local antigen-inexperienced cells, this is done in only one experiment, albeit repeated 3 times. The data suggest that antigen encounter during TRM formation induces sustained TGFBRIII expression that persists during the antigen-independent memory phase. It remains however, unclear why only antigen encounter in skin, but not already in the draining lymph nodes, induces sustained TGFBRIII expression. Further characterizing the dynamics of TGFBRIII expression on CD8+ T cells during priming in draining lymph nodes and over the course of TRM formation and persistence may shed more light on this question. Probing the role of this mechanism at other sites of TRM formation would also further strengthen their conclusions and enhance the significance of this finding.</p><p>A minor caveat of the study pertains to the use of FTY720 to block T cell egress from lymphoid tissues and thereby prevent a contribution of circulating memory OT-I T cells to the local recall response in skin. Since the half-life of FTY720 is less than a day in mice, its effects wear off rapidly. In their experiments, the authors discontinued treatment at the time of re-challenge, which may have allowed circulating T cells to contribute to the local recall response in skin, limiting the interpretability of the results somewhat. This concern is alleviated by the use of a second method (anti-Thy1.1-depleting antibodies) to eliminate circulating memory cells. For the benefit of readers intending to use this experimental strategy, it should however, be noted that FTY720 needs to be dosed continually (e.g. 3x/week at an appropriate dose) in order to sustain its effect.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.107096.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors set out to dissect the mechanistic basis of their previously published finding that encountering cutaneous antigen augments the persistence of CD8+ memory T cells that enter skin (TRM) (Hirai et al., 2021, Immunity). Here they use the same murine model to study the fate of CD8+ T cells after antigen-priming in the lymph nodes, (1) those that re-encounter antigen in the skin via vaccinia virus (VV) versus (2) those that do not encounter antigen in skin but rather are recruited via topical dinitrofluorobenzene (DNFB) (so-called &quot;bystander TRM&quot;). The authors' previous publication establishes that this first group of CD8+ TRM has a persistence advantage over bystander TRM under TGFb-limiting conditions. The current paper advances this finding by elucidating the role of TGFBR3 in regulating CD8+ TRM skin persistence upon topical antigen exposure. Key novelty of the work lies in generation and use of the CD8+ T cell-specific TGFBR3 knockout model, which allows them to demonstrate the role of TGFBR3 in fine tuning the degree of CD8+ T cell skin persistence and that TGFBR3 expression is promoted by CD8+ TRM encountering their cognate antigen upon initial skin entry. Future work directly measuring active TGFb in the skin under different conditions would help identify physiologic scenarios which yield active TGFb-limiting conditions, thus establishing physiologic relevance.</p><p>Strengths:</p><p>Technical strengths of the paper include (1) complementary imaging and flow cytometry analyses, (2) integration of their scRNA-seq data with the existing CD8+ TRM literature via pathway analysis, and (3) use of orthogonal models where possible. Using a vaccina virus (VV) model, with and without ovalbumin (OVA), the authors investigate how topical antigen exposure and TCR strength regulate CD8+ TRM skin recruitment and retention. The authors use both FTY720 and a Thy1.1 depleting antibody to demonstrate that skin CD8+ TRM expand locally following both a primary and secondary recall response to topical OVA application.</p><p>A conceptual strength of the paper is the authors' observation that TCR signal strength upon initial TRM tissue entry helps regulate the extent of their local re-expansion on subsequent antigen re-exposure. They achieved this by applying peptides of varying affinity for the OT-I TCR on the DNFB-exposed flank in tandem with initial VV-OVA + DNFB treatment. They then measured TRM expansion after OVA peptide rechallenge, revealing that encountering a higher affinity peptide upon skin entry leads to greater subsequent re-expansion. Additionally, by generating an OT-I Thy1.1+ E8i-creERT2 huNGFR Tgfbr3fl/fl (Tgfbr3∆CD8) mouse, the authors were able to elucidate a unique role for TGFBR3 in CD8+TRM persistence when active TGFb in skin is limited.</p><p>Weaknesses:</p><p>Overall, the authors' conclusions are well supported although there are some instances where additional controls, experiments, or clarifications would add rigor. The conclusions regarding skin localized TCR signaling leading to increased skin CD8+ TRM proliferation in-situ and increased TGFBR3 expression would be strengthened by assessing skin CD8+ TRM proliferation and TGFBR3 expression in models of high versus low avidity topical OVA-peptide exposure. The authors could further increase the impact of the paper by fully exploring whether TGFBR3 is regulated at the RNA or protein level; analysis of scRNAseq data included in the rebuttal did show an increase in Tgfbr3 RNA transcript levels in VV-treated compared to DNFB-treated back skin.</p><p>Quantification of the skin TRM population relies primarily on imaging analysis, which the authors indicate is more sensitive and consistent for quantifying this population. While flow cytometry is used to perform some phenotyping of TRMs, there remain some missed opportunities for more extensive analysis of markers expressed by this population. Finally, quantifying right and left skin draining lymph node CD8+ T cell numbers would clarify the skin specificity and cell trafficking dynamics of the authors' model.</p><p>This work heavily utilizes models developed and defined in previously published work (Hirai, T., et al., Competition for Active TGFβ Cytokine Allows for Selective Retention of Antigen-Specific Tissue- Resident Memory T Cells in the Epidermal Niche. Immunity, 2021. 54(1): p. 84-98.e5). Rather than repeating control experiments for this manuscript, the authors reference data included in this prior work. Thus, readers interested in a more in-depth understanding of these tools and concepts would be encouraged to read both papers.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.107096.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Weiss</surname><given-names>Eric</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Hirai</surname><given-names>Toshiro</given-names></name><role specific-use="author">Author</role><aff><institution>University of Osaka</institution><addr-line><named-content content-type="city">Osaka</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Haiyue</given-names></name><role specific-use="author">Author</role><aff><institution>university of pittsburgh</institution><addr-line><named-content content-type="city">pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Andrew</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Shannon</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Magill</surname><given-names>Ian</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Gillis</surname><given-names>Jacob</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Youran R</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ramcke</surname><given-names>Torben</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kurihara</surname><given-names>Kazuo</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Masopust</surname><given-names>David</given-names></name><role specific-use="author">Author</role><aff><institution>Harvard University</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Anandasabapathy</surname><given-names>Niroshana</given-names></name><role specific-use="author">Author</role><aff><institution>University of Minnesota</institution><addr-line><named-content content-type="city">Minnesota</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Zemmour</surname><given-names>David</given-names></name><role specific-use="author">Author</role><aff><institution>Weill Cornell Medicine</institution><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Mackay</surname><given-names>Laura</given-names></name><role specific-use="author">Author</role><aff><institution>university of chicago</institution><addr-line><named-content content-type="city">chicago</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Daniel H</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Harinder</given-names></name><role specific-use="author">Author</role><aff><institution>University of Pittsburgh</institution><addr-line><named-content content-type="city">Pittsburgh</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Weaknesses:</p><p>The main weakness in this paper lies in the authors' reliance on a single model to derive conclusions on the role of local antigen during the acute phase of the response by comparing T cells in model antigen-vaccinia virus (VV-OVA) exposed skin to T cells in contralateral skin exposed to DNFB 5 days after the VV-OVA exposure. In this setting, antigen-independent factors may contribute to the difference in CD8+ T cell number and phenotype at the two sites. For example, it was recently shown that very early memory precursors (formed 2 days after exposure) are more efficient at seeding the epithelial TRM compartment than those recruited to skin at later times (Silva et al, Sci Immunol, 2023). DNFB-treated skin may therefore recruit precursors with reduced TRM potential. In addition, TRM-skewed circulating memory precursors have been identified (Kok et al, JEM, 2020), and perhaps VV-OVA exposed skin more readily recruits this subset compared to DNFB-exposed skin. Therefore, when the DNFB challenge is performed 5 days after vaccinia virus, the DNFB site may already be at a disadvantage in the recruitment of CD8+ T cells that can efficiently form TRM. In addition, CD8+ T cell-extrinsic mechanisms may be at play, such as differences in myeloid cell recruitment and differentiation or local cytokine and chemokine levels in VV-infected and DNFB-treated skin that could account for differences seen in TRM phenotype and function between these two sites. Although the authors do show that providing exogenous peptide antigen at the DNFB-site rescues their phenotype in relation to the VV-OVA site, the potential antigen-independent factors distinguishing these two sites remain unaddressed. In addition, there is a possibility that peptide treatment of DNFB-treated initiates a second phase of priming of new circulatory effectors in the local-draining lymph nodes that are then recruited to form TRM at the DFNB-site, and that the effect does not solely rely on TRM precursors at the DNFB-treated skin site at the time of peptide treatment.</p></disp-quote><p>Thank you for pointing out these potential caveats to our work. We have considered the possibility that late application of peptide or cell-extrinsic difference could affect the interpretation of our results. We would like to highlight that in our prior publication on this topic [1], we found that OT-1 responses in mice infected with VV-OVA and VV-N (irrelevant antigen) yielded the same responses as in our VV-OVA/DNFB models. In addition, in both our prior publication and our current manuscript, application of peptide to DNFB painted sites results in T<sub>RM</sub> with a similar phenotype to those in the VV-OVA site. Thus, we are confident that it is the presence of cognate antigen in the skin that drives the augmented T<sub>RM</sub> fitness that we observe.</p><disp-quote content-type="editor-comment"><p>Secondly, although the authors conclusively demonstrate that TGFBRIII is induced by TCR signals and required for conferring increased fitness to local-antigen-experienced CD8+ TRM compared to local antigen-inexperienced cells, this is done in only one experiment, albeit repeated 3 times. The data suggest that antigen encounter during TRM formation induces sustained TGFBRIII expression that persists during the antigen-independent memory phase. It remains unclear why only the antigen encounter in skin, but not already in the draining lymph nodes, induces sustained TGFBRIII expression. Further characterizing the dynamics of TGFBRIII expression on CD8+ T cells during priming in draining lymph nodes and over the course of TRM formation and persistence may shed more light on this question. Probing the role of this mechanism at other sites of TRM formation would also further strengthen their conclusions and enhance the significance of this finding.</p></disp-quote><p>This is an intriguing point. We do not understand why expression of TGFbR3 in T<sub>RM</sub> required antigen encounter in the skin if T<sub>RM</sub> at all sites clearly have encountered antigen during priming in the LN. We speculate that durable TGFbR3 expression may require antigen encounter in the context of additional cues present in the periphery or only once cells have committed to the T<sub>RM</sub> lineage. A more detailed characterization of the dynamics of TGFbR3 expression in multiple tissues would be informative and represents a promising future direction for this project. We note that to robustly perform these experiments a reporter mouse would likely be a requirement.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Weaknesses:</p><p>Overall, the authors' conclusions are well supported, although there are some instances where additional controls, experiments, or clarifications would add rigor. The conclusions regarding skin-localized TCR signaling leading to increased skin CD8+ TRM proliferation in-situ and increased TGFBR3 expression would be strengthened by assessing skin CD8+ TRM proliferation and TGFBR3 expression in models of high versus low avidity topical OVA-peptide exposure.</p></disp-quote><p>Thank you for these helpful suggestions. We did not attempt these experiment as we were concerned that given the relatively modest expansion differences observed with the APL that resolving differences in TGFbR3 and BrdU would prove unreliable. However, this is something that we could attempt as we continue working on this project.</p><disp-quote content-type="editor-comment"><p>The authors could further increase the novelty of the paper by exploring whether TGFBR3 is regulated at the RNA or protein level. To this end, they could perform analysis of their single-cell RNA sequencing data (Figure 1), comparing Tgfbr3 mRNA in DNFB versus VV-treated skin.</p></disp-quote><p>As discussed above, a more detailed analysis of TGFbR3 regulation is of great interest. These experiments would likely require the creation of additional tools (e.g. a reporter mouse) to provide robust data. However, as suggested, we have re-analyzed our scRNAseq looking for expression of Tgfbr3. Pseudobulk analysis of cells isolated from VV or DNFB sites suggests that Tgfbr3 appears to be elevated in antigen-experienced TRM at steady-state (Author response image 1).</p><fig id="sa3fig1" position="float"><label>Author response image 1.</label><caption><title>Pseudobulk analysis by average gene expression of Tgfbr3 in cells isolated from either VV or DNFB treated flanks, divided by the average gene expression of Tgfbr3 in naïve CD8 T cells from the same dataset.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-sa3-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>For clarity, when discussing antigen exposure throughout the paper, it would be helpful for the authors to be more precise that they are referring to the antigen in the skin rather than in the draining lymph node. A more explicit summary of some of the lab's previous work focused on CD8+ TRM and the role of TGFb would also help readers better contextualize this work within the existing literature on which it builds.</p></disp-quote><p>We appreciate this feedback, and we have clarified this in the text.</p><disp-quote content-type="editor-comment"><p>For rigor, it would be helpful where possible to pair flow cytometry quantification with the existing imaging data.</p></disp-quote><p>Thank you for these suggestions. In terms of quantification of number of T<sub>RM</sub> by flow cytometry, we have previously demonstrated as much as a 36-fold decrease in cell count when compared to numbers directly visualized by immunofluorescence [1]. Thus, for enumeration of T<sub>RM</sub> we rely primarily on direct IF visualization and use flow cytometry primarily for phenotyping.</p><disp-quote content-type="editor-comment"><p>Additional controls, namely enumerating TRM in the opposite, untreated flank skin of VV-only-treated mice and the treated flank skin of DNFB-only treated mice, would help contextualize the results seen in dually-treated mice in Figure 2.</p></disp-quote><p>Without a source of inflammation (e.g. VV infection of DNFB) we see very few T<sub>RM</sub>in untreated skin. A representative image is provided (Author response image 2). A single DNFB stimulation does not recruit any CD8+ T cells to the skin without a prior sensitization [2].</p><fig id="sa3fig2" position="float"><label>Author response image 2.</label><caption><title>Representative images of epidermal whole mounts of VV treated flank skin, and an untreated site from the same mouse isolated on day 50 post infection and stained for CD8a.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-sa3-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>In figure legends, we suggest clearly reporting unpaired T tests comparing relevant metrics within VV or DNFB-treated groups (for example, VV-OVA PBS vs VV-OVA FTY720 in Figure 3F).</p></disp-quote><p>Thank you for this suggestion. The figure legends have been amended.</p><disp-quote content-type="editor-comment"><p>Finally, quantifying right and left skin draining lymph node CD8+ T cell numbers would clarify the skin specificity and cell trafficking dynamics of the authors' model.</p></disp-quote><p>We quantified the numbers of CD8 T cells in left and right skin draining lymph nodes by flow cytometry in mice at day 50 post VV infection DNFB-pull. We observe similar numbers of cells at both sites (Author response Image 3).</p><fig id="sa3fig3" position="float"><label>Author response image 3.</label><caption><title>Quantification of total number of CD8+ T cells in left and right inguinal lymph nodes.</title><p>Each symbol represents paired data from the same individual animal, and this is representative of 3 separate experiments.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-sa3-fig3-v1.tif"/></fig><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>(1) Figures 1D and S1C demonstrate that 80-90 % of TRM at both VV and DNFB sites express CD103+. In contrast, the sequencing data suggests the TRM at the VV site has much higher Itgae expression. Also, clusters 3 and 4, which express significantly more Itgae than all other clusters, together comprise only ~30% of CD8+ T cells at the VV-infected skin site. How can these discrepancies between transcript and protein expression be explained?</p></disp-quote><p>Thank you for these excellent comments. T<sub>RM</sub> at both VV and DNFB sites appear to express similarly high levels of CD103 protein in both the OT-I system as we previously published [1] and in a polyclonal system using tetramers. The lower penetrance of Itgae expression in the scRNAseq data we attribute to a lack of sensitivity which is common with this modality. However, the relative increased expression of Itgae in clusters 3 and 4 is interesting and may suggest increased Itgae production/stability. However, in the absence of any effect on protein expression, we chose not to focus on these mRNA differences.</p><disp-quote content-type="editor-comment"><p>(2) For the experiments in Figure 3D, in order to exclude a contribution from circulating memory cells, FTY720 should have been administered during the duration of, not prior to, the initiation of the recall response. The effect of FTY720 wears off quickly, so the current experimental setting likely allows for circulating cells to enter the skin. This concern is mitigated by the results of anti-Thy1.1 mAb treatment, but documenting the experiment as in Figure D will likely be confusing to readers.</p></disp-quote><p>Thank you for this comment. We relied on the literature indicating that the half-life of FTY720 in blood is longer than 6 days [3-5]. However, on reviewing this again, there are other reports suggesting a lower halflife. Thank you for pointing out this potential caveat. As mentioned above, we do not think this affects the interpretation of our data as similar results were obtained with anti-Thy1.1</p><disp-quote content-type="editor-comment"><p>(3) Similar to what is described in the weaknesses section, the data on TGFBRIII expression is lacking. When is TGFBRIII induced? In the LN during primary activation and it is then sustained by a secondary antigen exposure at the peripheral target tissue site? Or is it only induced in the peripheral tissue, and there is interesting biology to uncover in regard to how it is induced by the TCR only after secondary exposure, etc.?</p></disp-quote><p>Thank you for these comments. As discussed above, a more detailed analysis of TGFbR3 regulation is of great interest. These experiments would likely require the creation of additional tools (e.g. a reporter mouse) to provide robust data and are part of our future directions.</p><disp-quote content-type="editor-comment"><p>(4) As described in the weakness section, there could be TCR-independent differences between the VV-OVA and DNFB sites that lead to phenotypic changes in the TRMs that are formed there, both CD8+ T cell-intrinsic (kinetics; with regard to time after initial priming) and extrinsic (microenvironmental differences due to the nature of the challenge, recruited cell types, cytokines, chemokines, etc.). Since the authors report the use of both VV and VV-ova, we recommend an experimental strategy that controls for this by challenging one site with VV and another with VV-OVA concomitantly, followed by repeating the key experiments reported in this manuscript.</p></disp-quote><p>As discussed above, we have previously published a very similar experiment using VV-OVA and VV-N infection on opposite flanks [1].</p><disp-quote content-type="editor-comment"><p>(5) In Figure 6J please indicate means and provide more of the statistics comparing the groups (such as comparing VV-WT vehicle to VV-KO vehicle etc.), and potentially display on a linear scale as with all of the other figures looking at cells/mm2 to help convince the reader of the conclusions and support the secondary findings mentioned in the text such as &quot;Notably, numbers of Tgfbr3ΔCD8 TRM in cohorts treated with vehicle remained at normal levels indicating that loss of TGFβRIII does not affect TRM epidermal residence in the steady state&quot; despite it looking like there is a decrease when looking at the graph.</p></disp-quote><p>We appreciate the feedback on the readability of this figure, and so have updated figure 6J to be on a linear scale and added additional helpful statistics to the figure legend. The difference between Tgfbr3<sup>WT</sup> and Tgfbr3<sup>∆CD8</sup> at steady state is excellent point, and we agree that there could to be a trend towards reduction in the huNGFR+ T<sub>RM</sub> across both groups, even without CWHM12 administration. However, we did not see statistically significant reductions in steady-state Tgfbr3<sup>∆CD8</sup> T<sub>RM</sub>, but the slight reduction in both VV-OVA and DNFB treated flanks suggests that TGFßRIII may play a role in steady-state maintenance of all T<sub>RM</sub>. Perhaps with more sensitive tools to better visualize TGFßRIII expression, we could identify stepwise upregulation of TGFßRIII depending on TCR signal strength, possibly starting in the lymph node. We have also amended our description of this figure in the text, to allow for the possibility that a low, but under the level of detection amount of TGFßRIII could play a role in steady-state maintenance of both local antigen-experienced and bystander T<sub>RM</sub>.</p><disp-quote content-type="editor-comment"><p>Minor points:</p><p>(1) In describing Figure 4B, the term &quot;doublets&quot; for pairs of connected dividing cells is confusing.</p></disp-quote><p>Thank you for this comment, the term has been revised to “dividing cells” in the text and figure.</p><disp-quote content-type="editor-comment"><p>(2) Figure legend 4F: BrdU is not &quot;expressed&quot; .</p></disp-quote><p>Very true, it has been changed to “incorporation”.</p><disp-quote content-type="editor-comment"><p>(3) Do CreERT2 and/or huNGFR expressed by transferred OT-I cells act as foreign antigens in C57BL/6 mice, potentially causing elimination of circulating memory cells? If that were the case, this would not necessarily confound the read-out of TRM persistence studied here, since skin TRM are likely protected from at least antibody-mediated deletion and their numbers are not maintained by recruitment of circulating cells at stead-state. However, it would be useful to be aware of this potential limitation of this and similar models.</p></disp-quote><p>Thank you for raising the important technical concern. In our prior work [1] and this work, we monitor the levels of transferred OT-I cells in the blood over time. We have not observed rejection of huNGFR+ cells. We also note that others using the same system have also not observed rejection [6].</p><disp-quote content-type="editor-comment"><p>(4) In Figure 6J, means or medians should be indicated</p></disp-quote><p>This has been updated in Figure 6J.</p><disp-quote content-type="editor-comment"><p>(5) Using the term &quot;antigen-experienced&quot; to specifically refer to TRM at the VV site could be confusing, since those at the DNFB site are also Ag-experienced (in the LN draining the VV skin site).</p></disp-quote><p>We agree that it is a challenging term, as all T<sub>RM</sub> are memory cells. That is why in the text we refer to T<sub>RM</sub> isolated from the VV site as “local antigen experienced T<sub>RM</sub>.”, to try to distinguish them from bystanders that did not experience local antigen.</p><disp-quote content-type="editor-comment"><p>(6) The Title essentially restates what was already reported in the authors' prior study. If the data supporting the TGFBRIII-mediated mechanism is studied in more depth, maybe adding this aspect to the title may be useful?</p></disp-quote><p>Thank you for this suggestion. I think the current title is probably most suitable for the current manuscript but we are willing to change it should the editors support an alternative title.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>(1) Definition of bystander CD8+ TRM: The first paragraph of the introduction defines CD8+ TRM. To improve the clarity of this definition, we suggest being explicit that bystander TRM experience cognate antigen in the SDLNs but, in contrast to other TRM, do not experience cognate antigen in the skin.</p></disp-quote><p>Thank you, we have clarified this is in the text.</p><disp-quote content-type="editor-comment"><p>(2) Consider softening the language when comparing the efficiency of CD8+ recruitment of the skin between DNFB and VV-treated flanks. For example, substitute &quot;equal efficiency&quot; with &quot;comparable efficiency&quot; since it is difficult to directly compare the extent of inflammation between viral and hapten-based treatments.</p></disp-quote><p>We have adjusted this terminology throughout the paper.</p><disp-quote content-type="editor-comment"><p>(3) Throughout figure legends, we appreciate the indication of the number of experimental repeats performed. We suggest, either through statistics or supplemental figures, demonstrating the degree of variability between experiments to aid readers in understanding the reproducibility of results.</p></disp-quote><p>Thank you for this suggestion. In key figures we show data from individual mice across multiple experiments. Thus, inter-experiment variability is captured in our figures.</p><disp-quote content-type="editor-comment"><p>(4) Figure 1:</p><p>a) Add control mice treated with either vaccinia virus or DNFB and harvest back skin at day 52 to demonstrate baseline levels of polyclonal and B8R tetramer-positive CD8s in the epidermis. These controls would clarify the background CD8+ expansion that might occur in DNFB-treated mice in the absence of vaccinia virus.</p></disp-quote><p>This point was addressed above.</p><disp-quote content-type="editor-comment"><p>b) Figure 1: It would be helpful to see the %Tet+ population specifically in the CD103+ population, recognizing that the majority of the CD8+ from the skin are CD103+.</p></disp-quote><p>We did look only at CD103+ CD8 T cells from the skin for our tetramer analysis, so this has been clarified in the figure legend.</p><disp-quote content-type="editor-comment"><p>c) Provide a UMAP, very similar to 1H, where CD8+ T cells, vaccinia virus, and DNFB-treated flanks are overlaid.</p></disp-quote><p>Thank you for this suggestion. A UMAP combining aspects of 1G (cell types from the whole ImmgenT dataset) with 1H (our data) results in a figure that is very difficult to interpret. Thus, we have separated cell types across the entire ImmgenT data set (e.g. CD8+ T cells) and our data into 2 separate panels.</p><disp-quote content-type="editor-comment"><p>d) 1D: left flow plot has numbered axis while the right flow plot does not.</p></disp-quote><p>Thank you, this has been fixed.</p><disp-quote content-type="editor-comment"><p>(5) Figure 2:</p><p>a) In the figure legend, define what is meant by the grey line present in Figures 2C and 2D.</p></disp-quote><p>This has been updated in the figure legend.</p><disp-quote content-type="editor-comment"><p>b) Edit the Y axis of 2C and 2D to specify the TRM signature score.</p></disp-quote><p>This has been updated in the figure.</p><disp-quote content-type="editor-comment"><p>c) Include panel 1D from 1S into Figure 2 to help clarify for the reader what genes are expressed in the 0 - 5 clusters.</p></disp-quote><p>We appreciate the feedback, but we found the heatmap made the figure look too busy, so we feel comfortable keeping it available within supplemental figure 1.</p><disp-quote content-type="editor-comment"><p>d) In body of text explicitly discuss that the TRM module used to calculate a signature score was created using virus infection modules (HSV, LCMV and influenza) and thus some of the transcriptional similarity between the authors vaccinia virus treated CD8+ TRM and the TRM module might be due to viral infection rather than TRM status.</p></disp-quote><p>Thank you for this comment. We have now emphasized this point in the text.</p><disp-quote content-type="editor-comment"><p>(6) Figure 3:</p><p>a) If there are leftover tissue sections, it would be optimal to show specific staining for CD103. We recognize that this data has been previously published by the lab, but it would be ideal to show it once in this paper.</p></disp-quote><p>Unfortunately, we do not have leftover tissue sections, so we are unable to measure CD103 by I.F. in these experiments.</p><disp-quote content-type="editor-comment"><p>b) If you did collect skin draining lymph nodes in the Thy1.1 depletion model, it would be nice to see flow data showing the depletion effects in the skin draining lymph nodes in addition to the blood.</p></disp-quote><p>Unfortunately, we did not collect the skin draining lymph nodes, and do not have that data for the relevant experiments.</p><disp-quote content-type="editor-comment"><p>c) Figure 3 F &amp; G: Perform a T-test comparing vaccinia virus PBS to FTY720 and isotype to anti-Thy1.1 within the same treatment group. Showing no significance with these two comparisons would strengthen the authors' claims. Statistics can be described in legend.</p></disp-quote><p>We have included this analysis in the figure legend.</p><disp-quote content-type="editor-comment"><p>(7) Figure 4:</p><p>a) It would be helpful to have the CD69+/CD103+ population in this model discussed/defined more. The CD69 expression seen in 4E is lower than the reviewers would've predicted, and it would be interesting to see CD103 expression as well.</p></disp-quote><p>We have found that generally CD103 is a stronger marker for in the skin by flow, as CD69 staining is somewhat less robust in the colors we have chosen. By way of example, we present gating we did upstream in that experiment, gated previously on liveCD45+CD3+CD8+ events (Author response image 4)</p><fig id="sa3fig4" position="float"><label>Author response image 4.</label><caption><title>Representative flow cytometric plots showing CD69 and CD103 expression in gated live CD45+CD8+CD90.1+ cells isolates from VV-OVA or DNFB treated flanks.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-107096-sa3-fig4-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(8) Figure 5:</p><p>a) Define APL and its purpose in both the body of text and the figure legend.</p></disp-quote><p>We have clarified this in the text and the figure legend.</p><disp-quote content-type="editor-comment"><p>b) Using in-vivo BrdU, compare proliferation between high avidity N4 and low avidity Y3 OVA-peptide at the primary recall timepoint.</p></disp-quote><p>We considered this, but due to the lack of sensitivity of the BrdU incorporation and the relatively subtle phenotype of the Y3, we did not think the assay would be sensitive enough to identify differences.</p><disp-quote content-type="editor-comment"><p>(9) Figure 6:</p><p>a) Compare TGFBR3 expression in CD8+ T cells from mice receiving high avidity N4 versus low avidity Y3 OVA-peptide at the primary recall timepoint.</p></disp-quote><p>This point was discussed above.</p><disp-quote content-type="editor-comment"><p>b) Either 1) examine TGFBR3 mRNA expression in VV vs DNFB skin from scRNA-seq dataset or 2) perform a qPCR on epidermal CD8+ T cells from mice receiving high avidity N4 versus low avidity Y3 at the primary recall timepoint. This would help distinguish whether TGFBR3 regulation occurs at the mRNA versus protein level.</p></disp-quote><p>This point has been discussed above.</p><disp-quote content-type="editor-comment"><p>c) Figure 6A: Not required, but it seems like the TGFBR3 gate could be shifted to the right a bit.</p></disp-quote><p>The gates were set using FMO.</p><disp-quote content-type="editor-comment"><p>d) Figure 6C: What comparison is the asterisk indicating significance referring to?</p></disp-quote><p>It is the Dunnett’s test comparing VV-OVA to DNFB and untreated skin, the figure has been amended to clarify this point.</p><disp-quote content-type="editor-comment"><p>e) Figure 6: To increase the rigor of the claim that CWHM12 is creating a TGFb limiting condition, the authors could either 1) perform an ELISA or cell-based assay measuring active TGFb, 2) recapitulate results of 6J using monoclonal antibody against avb6 as done in Hirai et al., 2021, Immunity., or 3) examine Tgfbr3 mRNA expression in your single cell RNAseq data, comparing cluster 0 and cluster 3.</p></disp-quote><p>We are pleased to have the opportunity to show Tgfbr3 mRNA, which is above in figure R1.</p><disp-quote content-type="editor-comment"><p>(10) Material and methods:</p><p>Specify how the localization of the back skin used for imaging was made consistent between the right and left flanks.</p></disp-quote><p>We have updated this methodology in the text.</p><p>Literature Cited</p><p>(1) Hirai, T., et al., Competition for Active TGFβ Cytokine Allows for Selective Retention of Antigen-Specific Tissue- Resident Memory T Cells in the Epidermal Niche. Immunity, 2021. 54(1): p. 84-98.e5.</p><p>(2) Manresa, M.C., Animal Models of Contact Dermatitis: 2,4-Dinitrofluorobenzene-Induced Contact Hypersensitivity, in Animal Models of Allergic Disease: Methods and Protocols, K. Nagamoto-Combs, Editor. 2021, Springer US: New York, NY. p. 87-100.</p><p>(3) Müller, H.C., et al., The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice. Pulmonary Pharmacology &amp; Therapeutics, 2011. 24(4): p. 377-385.</p><p>(4) Nofer, J.-R., et al., FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice. Circulation, 2007. 115(4): p. 501-508.</p><p>(5) Brinkmann, V., et al., Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov, 2010. 9(11): p. 883-97.</p><p>(6) Andrews, L.P., et al., A Cre-driven allele-conditioning line to interrogate CD4<sup>+</sup> conventional T cells. Immunity, 2021. 54(10): p. 2209-2217.e6.</p></body></sub-article></article>